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 Complex diseases, such as cancer and heart disease, have complicated genetic 
architectures. The genetic risk factors underlying these diseases that represent public health 
challenges have not been comprehensively characterized, and a more thorough understanding of 
the genetic contributors to their multi-factorial etiologies may offer new insights into the optimal 
design of prevention and early intervention strategies. Combined with the advent of lower-cost, 
high-throughput genomic technologies, epidemiologic studies have enhanced potential to 
identify subgroups of the population with unique genetic etiologies and to fill in missing 
knowledge regarding genetic susceptibility to these complex phenotypes. A spectrum of genetic 
variants exists across the continuums of effect size and allele frequency, and with this spectrum, 
comes a variety of etiological mechanisms that require specialized detection methods. This 
dissertation applies genome-wide association study (GWAS) approaches, as well as a whole-
genome sequencing (WGS)-based co-segregation design, to identify susceptibility loci for two 
complex diseases: colorectal cancer (CRC) and severe congenital heart disease (CHD).  
 The first substantive chapter of this dissertation, Chapter 2, examines common genetic 
variation contributing to the etiology of CRC through a GWAS meta-analysis. This study, 
conducted among non-Hispanic whites and a founder population of Ashkenazi Jews from 





 The second dissertation project (Chapter 3) continues the search for CRC susceptibility 
loci with a targeted GWAS approach in Ashkenazi Jews from northern Israel. This study was 
designed to expand the search for microRNA (miRNA)-related polymorphisms important in the 
etiology of CRC across the genome and to investigate the association between genetic variants in 
miRNA target sites and CRC risk using a novel genotyping platform. This chapter highlighted 
several suggestive risk variants with predicted miRNA binding implications. It also replicated a 
recent association finding between a variant in INSR and CRC risk and demonstrated variability 
in INSR gene expression by genotype. Most importantly, this chapter demonstrated the potential 
for a targeted GWAS to identify candidate risk loci and to prioritize them for functional 
characterization. 
 Finally, Chapter 4 focuses on identifying genetic risk factors contributing to the etiology 
of complex CHD. The primary goal of this study was to identify rare genetic variation 
underlying the development of complex CHD through WGS of a family affected by hypoplastic 
left heart syndrome (HLHS) and conotruncal defects. The hypothesis was that the clustering of 
these anatomically distinct lesions was attributable to a more proximal defect in cardiogenesis. 
Ultimately, thirty-two variants across 29 genes were identified as causal candidates for future 
validation, replication, and follow-up epidemiologic studies.  
 Taken together, these three dissertation chapters enhance our understanding of genetic 
contributors to two complex phenotypes through detailed investigation of both large populations 
and a highly informative family. Future directions include, but are not limited to, fine mapping 
and functional studies of identified susceptibility loci for colorectal cancer and epidemiologic 




Chapter 1. Introduction 
 
1.1 The burden of complex diseases 
Complex diseases, such as colorectal cancer and congenital heart disease, are multi-
faceted collections of pathology with complicated etiologies. Several component causes combine 
to increase the risk of developing these disease phenotypes at both the individual and population 
levels
1
. Both colorectal cancer and congenital heart disease are caused by a combination of 
genetic factors, environmental influences, gene-by-gene interactions, and/or gene-by-
environment (GxE) interactions
2,3
. Despite their anatomical and etiologic diversity, all of these 
diseases have underlying pathogenic processes that can be described as complex. Their 
complicated natures make their etiologies challenging to study but also enrich the potential 
opportunities for early detection, tailored treatment, and prevention through modification of 
disease risk factors. 
The complex disease burden is currently on the rise in the United States (US) and across 
the developed world, as the global population structure ages, lifestyles become more sedentary, 
and diets change. The number of deaths due to chronic diseases now far exceeds those 
attributable to communicable diseases in the Western world
4
. Congenital heart disease and 
colorectal cancer, the two complex conditions under study in this dissertation, are representative 
of the broader classes of diseases of heart disease and cancer that rank as the top one and two 
leading causes of death in the US, respectively
4
. Particularly pertinent to this dissertation, it is 
important to note that colorectal cancer (CRC) and congenital heart disease (CHD) are two 
conditions with long-term implications for quality of life
5-7
 and economic burden
8,9




healthcare system. Etiologic research constitutes the first step towards informing prevention, 
screening, and therapeutic development.  
Some recent efforts to combat complex diseases have focused on personalized or 
“precision” medicine that focuses on the development of tailored strategies to treat the right 
patient with the right therapeutic or intervention at the right time based on genomic and clinical 
profiles
10,11
. In addition, a major objective from the epidemiologic perspective in the era of 
genomic medicine is to understand the determinants of disease in a population with the goal of 
informing primary or secondary prevention efforts. In order to discover methods for early 
intervention and ultimately prevention, we must first better understand the underlying causes of 
these complex diseases and their development processes. Among the multitude of potential 
disease drivers, the focus of this dissertation is on the genetic risk factors conferring 
susceptibility to CRC and CHD.  
1.2 Heritability of CRC and CHD 
Narrow-sense heritability is a population-level concept referring to the proportion of 
phenotypic variance attributable to the additive effects of genetic factors. For a binary trait, each 
individual is assumed to have a liability of developing disease derived from an underlying 
distribution in the population. In this case, heritability captures the proportion of variance in 
disease risk attributable to additive genetic factors. Heritability estimates for CRC and severe 
CHD range from 32 to 35% (95% confidence interval (CI): 10%-48%) 
12,13
 and 74% (95% CI: 
50%-96%)  to 99% (95% CI: 59%-100%) (depending on the lesion under study)
14,15
, 
respectively. These heritabilities indicate that inherited genetic factors play a substantial role in 
the etiologic landscape of these two complex diseases, with an even greater contribution to the 
phenotypic variance of risk for CHD.  However, the specific genetic risk factors underlying these 




referred to as the missing heritability problem
2,16
. Further, for those implicated genetic loci, 
information about the biological functionality of the variation remains limited.  
A more thorough understanding of the genetic contributors to these complex phenotypes 
may offer new insights into their underlying biology. Studies of both common complex 
manifestations and extreme phenotypes of the same disease state may complement each other to 
inform potentially shared genes or pathways important for pathogenesis..  
1.3 Paradigm shift in genetic epidemiology study design 
Over the past two decades, major shifts in the paradigm of genetic epidemiological 
investigations of complex disease etiology have occurred alongside improvements in genetic 
technologies and advances in our understanding of genetic variants on the population scale
17
. 
Prior to the first publication of the human genome sequence in 2001
18
 and continuing through the 
early 2000s, the literature base was saturated with candidate gene single nucleotide 
polymorphism (SNP) association studies, often lacking statistical power. At that time, tools were 
not broadly available for testing agnostic hypotheses, so researchers relied solely upon existing 
knowledge about disease biology to drive their study designs
19
. Subsequently, the International 
Haplotype Map (HapMap) Project catalogued common genetic variation across European, 
African, and East Asian populations and demonstrated that between half of a million and a 
million SNPs could tag nearly 90% of all common variation (minor allele frequency (MAF) 
>=5%) across the genome due to linkage disequilibrium patterns
20-23
.  Linkage disequilibrium 
refers to the non-random association of specific alleles at neighboring genetic loci that results 
from several population genetic forces. Leveraging this concept allowed for the development of 





Between 2005 and 2007, genome-wide association studies (GWAS) leveraging 
haplotype-tagging SNP genotyping chips gained traction, allowing researchers to conduct 
hypothesis-free searches for common variants influencing risk of common diseases
24
. From the 
mid- to late-2000’s, the advent of “next-generation” sequencing (NGS) technologies took hold, 
and an era of even higher-throughput, whole-genome characterization and genetic variant 
identification began alongside GWAS. As this most recent set of technologies has driven the 
rapid decline in whole-genome and targeted deep sequencing costs, researchers have found 
themselves circling back to the importance of biologically-driven hypotheses and candidate gene 
or pathway studies of both common and rare genetic variation
19,25
.  It has long been recognized 
that a spectrum of genetic variants conferring disease risk exists across the continuums of effect 
size and allele frequency. However, throughout the aforementioned evolution in human genetics, 
statistical genetics, and genetic epidemiology, an active debate has arisen regarding whether rare 
or common variants contribute more substantially to complex disease etiologies
2,26,27
. The 
combination genetic technologies developed over the last decade now allow for the interrogation 
of variation across the frequency spectrum. 
1.4 Summary of chapters 
Paralleling the genetic epidemiology paradigm shift outlined above, this dissertation is 
designed to show by example how three different quantitative approaches can be leveraged to 
investigate the genetic etiologies underlying complex diseases. Specifically, the following 
chapters demonstrate how unique study designs and quantitative approaches have the potential to 
characterize novel genetic contributors to CRC and CHD development, particularly in subgroups 
of the population.  
The first two substantive chapters of this dissertation focus on elucidating novel genetic 




dissertation explores low penetrance susceptibility loci for CRC through a GWAS meta-analysis. 
The common disease common variant hypothesis proposes that a multitude of common, low- to 
moderate-penetrance susceptibility alleles account for a substantial portion of the unidentified 
genetic risk factors
24,26,28-31
. Tools that measure genetic variation across genome in an unbiased 
fashion offer an informative approach to identify novel risk loci when used in conjunction with 
association study methods. Chapter 2 expands upon the traditional agnostic GWAS approach by 
focusing on susceptibility locus discovery in a founder population of Ashkenazi Jews from a 
population-based study in northern Israel, the Molecular Epidemiology of Colorectal Cancer 
(MECC) study, with power for effect detection supplemented by the inclusion of non-Hispanic 
whites from the Colon Cancer Family Registry (CFR). I hypothesize that unidentified low 
penetrance susceptibility alleles confer risk to CRC.  
In Chapter 3, I introduce a targeted GWAS approach to study genetic risk factors for 
CRC, again in the Ashkenazi Jewish population of northern Israel from the MECC study. Many 
targeted studies to date have focused on genetic variation in candidate genes from known 
biological pathways involved in CRC disease etiology. Instead, this chapter takes a new 
approach and studies the global impact of variation in genes affecting a pathway for regulatory 
control of gene expression. MicroRNAs (miRNAs) are short ribonucleic acid (RNA) molecules 
that act as post-transcriptional regulators of gene expression via binding to the 3’ untranslated 
regions (3’-UTRs) of one or more messenger RNAs (mRNAs)
32
. This binding acts to repress 
translation of the messenger into protein or to signal for degradation of the targeted mRNA. 
SNPs found in the miRNA sequence and/or corresponding binding sites can affect the fidelity of 
this miRNA-mRNA interaction, and ultimately, alter the risk of tumor development
33
. The study 




cancer etiology across the genome and to investigate the association between thousands of 
genetic variants in miRNA target sites in 3’-UTR regions and miRNA-encoding genes and CRC 
risk using a novel genotyping platform. Further, this chapter bioinformatically characterizes the 
potential functional consequences with respect to miRNA binding of the most statistically 
significantly associated SNPs. Given that our research group was given early, prioritized access 
to a novel commercial platform to assess miRNA-related polymorphisms before it was released 
to the general public, I am confident that this represents the first study to examine associations 
between genetic variation in miRNA target sites and CRC risk using a genome-wide approach. 
In the final substantive chapter (Chapter 4), this dissertation shifts to the frontier of NGS 
in genetic epidemiology and explores whole-genome sequencing (WGS) along with family-
based co-segregation analysis as a method for identifying genes and pathways involved in CHD 
etiology. This approach agnostically identifies potentially causal novel and rare variants in genes 
or pathways important for disease development for follow-up in larger populations. I hypothesize 
that potentially causative genetic variants for complex CHD in a family affected by hypoplastic 
left heart syndrome (HLHS) and conotruncal lesions will be identifiable through WGS and 
informative regarding candidate genes or pathways for future investigations. This chapter 
leverages family data as a method to screen for and prioritize genes and/or pathways for study at 
the population level. Finally, Chapter 5 summarizes the key findings from this dissertation and 
the dissertation’s contributions to the field of genetic epidemiology. 
1.5 Overview 
In summary, genetic epidemiological study designs have evolved over the past decade 
beginning with candidate gene association studies. GWAS have spurred renewed interest in 
biological pathway and expression quantitative trait loci (eQTL) analyses for both common and 




the forefront of rare variant study for Mendelian and complex diseases. This dissertation aims to 
demonstrate by example that both common and rare variants can play important roles in the 
genetic etiology of complex diseases. Further, I hope to convey that both population-based and 
family-based study designs add value to understanding the complicated milieu of genetic risk 
factors for complex phenotypes. Each of the study designs outlined above offer unique insights 
about genetic contributors to CRC and CHD, and although the focus here is on two specific 
complex conditions, these methods are broadly applicable to the study of genetic risk factors for 




Chapter 2. A novel low-penetrance risk locus for colorectal cancer at 4q32.2: findings from 
a genome-wide association study meta-analysis 
 
2.1 Background 
 In the United States, colorectal cancer (CRC) has the third highest age-adjusted incidence 
of all cancer sites in men and women and ranks second
 




Worldwide, it is the second
 
most commonly diagnosed cancer in women and third in men; it 
ranks as the fourth most common cause of cancer death
35,36
. Contributing to these summary 
statistics are several special populations bearing a disproportionate burden of CRC incidence. 
Nearly 60% of CRC cases occur in developed regions of the world
35,36
. Among these high 
burden groups is the genetically homogeneous founder population of Ashkenazi Jewish 
individuals, with incidence rates comparable to or higher than those experienced by non-
Hispanic whites in the United States, despite differences in dietary and lifestyle risk factors
34
. 
Comparing population subgroups from Israel, age-standardized incidence among Ashkenazi 
(European or American born) Jews is 41.9 per 100,000, strikingly higher than Sephardi (Asian or 
African born) Jewish, Israel-born Jewish, and Israeli non-Jewish rates (25.5, 32.8, and 10.1 per 
100,000, respectively)
37
. This stratification of Israeli incidence rates, with Ashkenazi Jews 
experiencing the highest burden, has been maintained consistently over time
38
. 
 Well-characterized epidemiologic risk factors for CRC include age, personal or family 
history of colorectal polyps or CRC, ethnicity, smoking, heavy alcohol use, high-fat diet, 
physical inactivity, and obesity
39
. In addition to these established factors, inherited susceptibility 




founder populations such as Ashkenazi Jews and Newfoundlanders
40
 . In total, inherited genetic 
factors  account for 32-35% of the variation in risk for developing CRC
12,13
. However, only 2-
6% of all CRC cases occur as part of well-characterized familial cancer syndromes driven by 
rare, highly penetrant, germline mutations
13,41-43
. For example, the autosomal dominant condition 
Lynch Syndrome, formerly described as hereditary non-polyposis colorectal cancer, is caused by 
germline mutations in DNA mismatch repair genes (MLH1, MSH2, MSH6, PMS2, or 
EPCAM)
44,45
. Further, the cause of familial adenomatous polyposis, an autosomal dominant 
syndrome characterized by excessive polyp formation in the colorectum and an exceptionally 
high risk of CRC, is a mutation in the adenomatous polyposis coli (APC) gene
44,46
. Also, 
autosomal recessive conditions such as MYH-associated polyposis meaningfully contribute to the 
CRC burden. 
 Genetic risk factors contributing to the remaining familial and sporadic CRC cases have 
yet to be fully elucidated. Despite the relatively thorough characterization of genetic changes 
driving progression from normal epithelium to metastatic disease, it is unclear outside of the 2-
6% syndromic cases which variants predispose individuals to initiate this disease course. Among 
the potential sources of missing heritability, the common disease common variant hypothesis 
proposes that a combination of many common, low- to moderate-penetrance susceptibility alleles 
account for a substantial portion of these unidentified genetic risk factors
24,26,28-31
. Large 
populations and genetic tools that take an agnostic view of the genome offer an informative 
approach to address this hypothesis and to identify novel risk loci. 
 Traditional genome-wide association studies (GWAS) leverage linkage disequilibrium 
(LD) between haplotype-tagging and/or imputed single nucleotide polymorphisms (SNPs) and 




associations between common genetic variants (minor allele frequency (MAF) >= 5%) and 
binary disease status or quantitative traits
24
. Several GWAS of CRC risk have identified over 
twenty low-penetrance susceptibility loci
47-60
. Some risk loci have been identified in genes 
contributing to pathways with existing links to CRC pathogenesis, such as the Wnt and 
transforming growth factor-beta (TGF-β) signaling pathways
61
. However, these studies have also 
identified a number of loci in novel regions. Although the functional significance and clinical 
relevance of most loci remain largely undetermined, several critical genes and regulatory regions 
have been well defined (Table 2.1). Similar to GWAS results from other complex diseases, the 
loci identified thus far explain only a small proportion of CRC’s heritability and have limited 
utility for clinical risk prediction
2,62-65
. Although some have argued that a large number of 
higher-effect rare variants are the primary genetic drivers of complex diseases
66
,  it is likely that 
variants of multiple frequencies and effect sizes contribute
2,24,26,27
. Given the large number of 
risk loci successfully identified for breast and prostate cancer, we hypothesize that additional 
common, low penetrance loci for CRC remain that will require larger sample sizes or studies in 
specific populations to detect. Comprehensively characterizing these risk-conferring regions 
could offer new insights into the complex biology of CRC. 
With the goal of identifying novel susceptibility loci, we conducted a GWAS meta-
analysis of case-control studies of CRC in two populations: Ashkenazi Jews from the Molecular 
Epidemiology of Colorectal Cancer (MECC) study and non-Hispanic whites from the Colon 
Cancer Family Registry (CFR). Further, we replicated the strongest findings of genetic 
association from the meta-analysis in an independent set of Israeli MECC cases and controls to 
highlight variants most likely to influence the etiology of CRC in Ashkenazi Jews (AJ).  Finally, 




power for detecting associated genetic variants and to fine map a genome-wide significant 
finding. This study design provides the potential to identify risk alleles for future functional 
studies that are important across European sub-populations as well as genetic variants unique to 




Table 2.1. Published genome-wide significant (p<5x10
-8
) CRC risk loci. Aus = Australia. 
SNP CHR BP Locus (nearby gene) Study population Reference 
rs6691170 1 222045446 
1q41 (DUSP10) 
Europe Houlston et al 2010
56
 
rs6687758 1 222164948 Europe Houlston et al 2010
56
 
rs11903757 2 192587204 2q32.3 (NABP1) 
Europe, US, Canada, Aus, 
East Asia 
Peters et al 2012a
58
 
rs10936599 3 169492101 3q26.2 (MYNN) Europe Houlston et al 2010
56
 
rs647161 5 134499092 5q31.1 (AK026965) East Asia, Europe Jia et al 2013
67
 
rs1321311 6 36622900 6p21 (CDKN1A) 
Europe, US, Canada, Aus, 
East Asia 
Dunlop et al 2012
59
 
rs7758229 6 160840252 6q25.3 (SLC22A3) East Asia Cui et al 2011
68
 
rs16892766 8 117630683 8q23.3 (EIF3H) Europe Tomlinson et al 2008
54
 
rs10505477 8 128407443 
8q24 (MYC) 
Europe, Canada, 
Newfoundland, US, Israel 
Zanke et al 2007
49
 
Gruber et al 2007
47
 
rs6983267 8 128413305 
Europe, Canada, 
Newfoundland, US 
Zanke et al 2007
49
 
Haiman et al 2007
69
 
Tomlinson et al 2007
51
 
Hutter et al 2010
70
 
rs7014346 8 128424792 
Europe, Canada, East Asia, 
Israel 
Tenesa et al 2008
55
 
rs719725 9 6365683 9p24 (TPD52L3) Europe, US 
Tomlinson et al 2008
54
 
Kocarnik et al 2010
71
 
rs10795668 10 8701219 10p14 (LOC338591) Europe Tomlinson et al 2008
54
 
rs3824999 11 74345550 11q13.4 (POLD3) 
Europe, US, Canada, Aus 
East Asia 
Dunlop et al 2012
59
 
rs3802842 11 111171709 11q23 (C11orf93) 
Europe, Canada, East Asia, 
Ashkenazi Jews 
Tenesa et al 2008
55
 
rs10774214 12 4368352 12p13.32 (CCND2) East Asia, Europe Jia et al 2013
67
 
rs7136702* 12 50880216 
12q13.12 (LARP4) 
Europe Houlston et al 2010
56
 
rs11169552 12 51155663 Europe Houlston et al 2010
56
 
rs4444235 14 54410919 
14q22.2 (BMP4) 
Europe, US, Canada, Aus 
Houlston et al 2008
52
 
Tomlinson et al 2011
60
 
 rs1957636 14 54560018 Europe, US, Canada, Aus Tomlinson et al 2011
60
 




Europe, US, Canada, 
Australia 
Tomlinson et al 2011
60
 
rs4779584 15 32994756 Europe, US, Canada, Aus 
Jaeger et al 2008
48
 
Tomlinson et al 2011
60
 
 rs11632715 15 33004247 Europe, US, Canada, Aus Tomlinson et al 2011
60
 
rs9929218 16 68820946 16q22.1 (CDH1) Europe Houlston et al 2008
52
 
rs4939827 18 46453463 18q21 (SMAD7) 
Europe, Canada, East Asia, 
Israel 
Broderick et al 2007
50
 




rs10411210 19 33532300 19q13.1 (RHPN2) Europe Houlston et al 2008
52
 
rs961253 20 6404281 
20p12.3 (BMP2) 
Europe, US, Canada, Aus 
Houlston et al 2008
52
 




rs4813802 20 6699595 
Europe, US, Canada, Aus, 
Newfoundland, Israel 
Tomlinson et al 2011
60
 
Peters et al 2012b
57
 




rs5934683 X 9751474 Xp22.2 (SHROOM2) 
Europe, US, Canada, Aus, 
East Asia 
Dunlop et al 2012
59
 




2.2  Materials and methods 
2.2.1 Study populations 
 The discovery meta-analysis was conducted using germline DNA from two separate 
case-control studies, the Molecular Epidemiology of Colorectal Cancer (MECC) study, and the 
Colon Cancer Family Registry (CFR). The replication dataset consisted of an independent set of 
MECC participants. Demographic and clinical characteristics of participants with high quality 






Table 2.2. Demographic and clinical characteristics of genotyped participants after quality 
control from the Molecular Epidemiology of Colorectal Cancer (MECC; ndiscovery = 983; nreplication 
= 1,962) and Colon Cancer Family Registry (CFR; ndiscovery = 2,977) case-control studies. 
 
Discovery Meta-Analysis Replication  
 
MECC 
 Illumina Omni2.5M  
CFR - Illumina Human 
1M, 1M-Duo, and 
Omni1-Quad 
MECC  














Age  [mean(sd)] 71.6 (10.1) 72.8 (10.2) 52.7 (11.1)  59.9 (11.0)  71.0 (11.0) 
73.7 
(11.1) 
Sex (%)             
Male 265 (54.6)  264 (53.0) 983 (49.7)  478 (47.8)  563 (49.8) 420 (50.5) 
Female 220 (45.4)  234 (47.0) 994 (50.3)  521 (52.2)  568 (50.2) 411 (49.5) 
Ethnicity (%)             
Ashkenazi  470 (96.9)  493 (99.0)  0  0  1129 (99.8) 804 (96.8) 
Sephardi 0 0 0  0  0 9 (1.1) 
Ashkenazi/ 
non-Jewish  8 (1.6)  2 (0.4)  0  0  1 (0.1) 3 (0.4) 
Ashkenazi/ 
Sephardi  1 (0.2)  2 (0.4)  0  0  1 (0.1) 12 (1.4) 
Non-Jewish, 
non-Arab  6 (1.2)  1 (0.2) 0  0  0 0 
Non-Hispanic 
White 0 0 1977 (100) 999 (100) 0 0 
Missing 0 0  0 0  0 3 (0.4) 
1st degree relative 
with CRC (%)             
Yes 65 (13.4) 41 (8.2) - -  135 (11.9) 71 (8.5) 
No 419 (86.4) 457 (91.8) -  999 (100)  985 (87.1) 757 (91.1) 
Missing 1 (0.2) 0 -  -  11 (1.0) 3 (0.4) 
Cancer site (%)             
Left colon 269 (55.5)  - 628 (31.8)  - 402 (35.5) - 
Right colon 181 (37.3)  - 577 (29.2)  - 343 (30.3) - 
Colon (Not Other- 
wise Specified) 0 - 43 (2.2)  - 0 - 
Rectum 31 (6.4)  - 729 (36.9) - 300 (26.5) - 
Other 4 (0.8) -  0 - 51 (4.5) - 





2.2.1.1 Molecular Epidemiology of Colorectal Cancer Study (MECC) 
The Molecular Epidemiology of Colorectal Cancer Study (MECC) is a population-based, 
case-control study of pathologically-confirmed, incident cases of CRC recruited from a 
geographically-defined region of northern Israel
72
.  Participant recruitment began in 1998 and 
remains on-going. Individually-matched controls with no prior history of CRC are selected from 
the same source population that gave rise to cases using the Clalit Health Services database. 
Matching factors include age, sex, Jewish ethnicity (Jew versus non-Jew), and primary clinic 
site. Subjects are interviewed to obtain demographic and clinical information, family history, and 
dietary habits. Biospecimens including blood, paraffin blocks, and snap frozen tumors are also 
collected. The discovery phase of this GWAS meta-analysis leverages data for 485 AJ cases and 
498 AJ controls from MECC. Case selection for genotyping in this phase enriched for colon 
cancer (not rectal cancer), enriched for a specific stage distribution for a separate GWAS study 
of stage and prognosis, and excluded cases with microsatellite instable (MSI-H) tumors. The 
replication stage utilizes MECC genotypes from 1,131 AJ cases and 831 AJ controls. Replication 
stage cases were unselected for cancer site, stage, or MSI (Table 2.2).  
2.2.1.2 Colon Cancer Family Registry (CFR) 
The Colon CFR is a consortium of six centers across North America and Australia, 
organized to create a comprehensive resource for clinical and epidemiologic studies of CRC 
57,73
. 
The six centers include the University of Southern California (USC), Fred Hutchinson Cancer 
Research Center (FHCRC), Mayo Clinic, Cancer Care Ontario, Hawaii Cancer Registry, and the 
University of Melbourne. The registry contains family history, clinical history, and risk factor 
data on approximately 37,000 subjects (including nearly 10,000 probands and 27,000 affected or 




incident cases of CRC via population-based cancer registries or clinical centers as well as general 
population or proband-identified controls. Phase II recruitment (2002-2007) included incident 
probands with CRC diagnosed under age 50 and additional clinic-identified families. As 
described previously, those selected from Phase I for the study’s initial genome-wide scan (Set 
1) were population-based cases and age- and sex-matched controls from the following three 
centers: FHCRC, Cancer Care Ontario, and Melbourne
74
. Phase II participants selected for 
genotyping (Set 2) included population-based cases from all six study sites and same-generation 
family controls. However, only Phase II cases are included in this analysis, and family-based 
controls were excluded. Case selection for genotyping from both Sets 1 and 2 was enriched for 
age at onset prior to 50 or family history of CRC. All subjects self-reported as being of non-
Hispanic white race, and this was verified using genotype data. Further, controls reported no 
family or personal CRC history. In total, the discovery GWAS meta-analysis uses 1,977 
population-based cases from Phases I and II and 999 age- and sex-matched controls from Phase 
I.  
2.2.2 Genotyping and quality control 
2.2.2.1 Discovery meta-analysis 
 Germline DNA was extracted from peripheral blood samples for both MECC and CFR 
participants. MECC DNA was genotyped in two batches using the Illumina HumanOmni 2.5S-
v1 BeadChip, which measures nearly 2.4 million SNPs.  Batch 1 (414 cases and 155 controls) 
was run at Case Western Reserve University (CWRU) for the purpose of a GWAS study of stage 
and prognosis, and batch 2 (104 cases and 376 controls) was run at the University of Michigan 
(UM) to create a balanced design of cases and matched controls. Colon CFR samples were 




(CFR Set 1), and the Omni1-Quad (CFR Set 2 controls), each containing approximately 1.2 
million common loci.  
MECC genotype data were cleaned based on quality control (QC) metrics at the 
individual subject and SNP levels (Figure 2.1). Samples with >5% missing genotypes, sex 
mismatches (between self-reported and genotypic predicted sex), duplicate samples, and those 
with excess homozygosity were identified and subsequently removed. SNPs with <95% call rate 
were excluded, and those inconsistent with Hardy Weinberg Equilibrium (HWE) in controls 
were flagged for individual review but not removed. Principal components analysis (PCA) was 
conducted on approximately 100,000 randomly selected markers (after LD-pruning) using the 
pcaMethods Bioconductor package
75
 in R to identify ethnic outliers. These same principal 
components were retained to adjust for confounding due to population stratification. Pairwise 
plots of principal components (PCs) 1-3 on the final analysis dataset are in Figure 2.2. 
 










Figure 2.2. Pairwise plots of principal components from the discovery phase MECC Omni 
samples. Legend shows self-reported ethnicity. 
 CFR genotype data was cleaned using comparable parameters, and the methods applied 
for CFR Set 1 genotypes have been detailed elsewhere
74
.  Briefly, the QC criteria excluded 




previous genotype data, and unanticipated genotype concordance or identity-by-descent (IBD) 
with another sample. PCA based on a panel of ancestry information markers (AIMs) was 
conducted using Eigenstrat
76
, followed by comparison to HapMap II CEU participants from 
Utah, to identify and exclude ethnic outliers. SNP level exclusions were made for markers with 
more than two alleles, no “rs” identification number, poor genotype concordance in the same 
individuals across platforms, and low call rate (<90%). Pairwise plots of PCs 1-4 on the final 





Figure 2.3. Pairwise plots of principal components from the discovery phase CFR samples. All 




2.2.2.2 Replication analysis 
An independent set of MECC germline DNA samples were genotyped as part of the 
National Cancer Institute (NCI)-sponsored Colorectal Transdisciplinary (CORECT) Study 
Consortium and served as the replication dataset for this study. These MECC participants had 
similar distributions of key demographic and clinical covariates to the discovery stage MECC 
subjects with the exception of cancer site and MSI (Table 2.2). Genotyping was performed via 
hybridization to a custom Affymetrix
 
genome-wide platform (the Axiom
®
 CORECT Set) 
containing approximately 1.3 million SNPs and indels spread across two physical genotyping 
chips (pegs). The quality control and filtering pipeline resulted in a final analysis dataset 
containing 1131 cases, 831 controls, and 1,230,678 genetic markers (Figure 2.4). PCA was 
conducted using Eigenstrat
76
 based on a set of 2,884 AIMs derived from the literature and the 
Illumina
 




 Exome Array. Pairwise 
plots of PCs 1 and 2 on the final analysis dataset are in Figure 2.5. 
 
Figure 2.4. Quality control and filtering pipeline for MECC Axiom
®
 replication samples prior to 





Figure 2.5. PC1 versus PC2 plot from the replication phase MECC Axiom samples. Legend 
shows self-reported ethnicity. 
2.2.3 Imputation 
 To analyze genotype data generated from three different platforms that measure different 
genetic markers and to increase the coverage of variation that is measurable across the genome, 
imputation of genotypes was performed for both autosomal and X chromosome markers. First, 
genotypes were pre-phased into best-guess haplotypes with SHAPEIT (SHAPEIT.v1.ESHG) to 
increase the computational efficiency of downstream steps
77,78
. Default parameters were applied 
with the exception of effective-size=11,418. Then, IMPUTE2 (IMPUTE v2.2.2) was used to 
impute missing genotypes for study samples based on the cosmopolitan panel of reference 
haplotypes from Phase I of the 1000 Genomes Project (March 2012 release; n = 1092)
79
. Among 
the panel’s ethnically diverse samples, it includes 500 samples from 5 different Caucasian 
populations: Utah residents with Northern and Western European ancestry, Toscani in Italy, 




contains over 39 million autosome and X chromosome SNPs, indels, and structural variants. 
Default parameters for IMPUTE2 were applied except for k_hap=1038 and buffer=500. In order 
to enter subsequent statistical analysis steps, genetic markers resulting from the imputation had 
to pass stringent imputation quality and accuracy filters (info>=0.7, certainty>=0.9, and 
concordance>=0.9 between directly measured and imputed genotypes after masking input 
genotypes (for genotyped markers only)). Further, we restricted our SNP list to those with study-
specific MAF >=1%. Following imputation and QC, 9,009,669, 8,304,060, and 9,177,523 SNPs 
were available for analysis in the MECC discovery, CFR discovery, and MECC replication, 
respectively. 
2.2.4 Statistical analysis 
2.2.4.1 Discovery GWAS meta-analysis 
The discovery MECC and CFR datasets were first analyzed in a study-specific fashion, 
allowing for adjustment for appropriate covariates. Then, study-specific results were analyzed 
using an inverse-variance-weighted, fixed-effects meta-analysis which assumed homogeneity of 
effects across the two studies. In each study, to examine the association between each variant and 
CRC risk, we specified a log-additive genetic model, where each additional copy of the minor 
allele was assumed to confer the same magnitude of risk or protection. Each SNP was coded as a 
dosage, the expected number of effect alleles. We calculated beta coefficients and corresponding 
odds ratios (OR), standard errors, 95% confidence intervals, and p-values using unconditional 
logistic regression. For MECC, models were adjusted for age, sex, 3 PCs, and genotyping batch 
(in the event that differential genotyping errors occurred across the two genotyping centers). For 
CFR, we adjusted for age, sex, 4 PCs, and recruitment site (in 3 groups). For both studies, higher 




These models were used to examine the odds ratio for CRC risk associated with each additional 
copy of the minor allele (or minor allele dosage) for a given SNP, after adjusting for all 
covariates in the model.  
For markers with matching identification names and/or chromosome, base pair, and 
alleles across the two studies, we conducted a meta-analysis of point estimates and standard 
errors using an inverse-variance-weighted, fixed-effects approach. This method, implemented in 
METAL, calculates a summary estimate of effect for each marker through summation of inverse-
variance weighted betas across studies, divided by the summed weights
80
. A quantile-quantile 
(Q-Q) plot was generated to examine the distribution of meta-analysis p-values compared to the 
distribution under null expectations. The genomic control lambda (GC λ) associated with the 
observed p-value distribution was calculated to identify evidence of p-value inflation, likely due 
to population stratification. GC λ is the median observed squared Z statistic divided by the 
median expected squared Z (0.455) based on a null Χ
2
 with 1 degree of freedom. A Manhattan 
plot showing p-values sorted by chromosomal position was generated to provide a visual 
illustration of top hit regions across the genome. SNPs with nominally significant p-values 
(p<0.05) were selected for replication in the second phase of this study (nmarker = 492,866). 
Further, to ensure that our genotyping and subsequent analysis was able to detect previously 
published risk loci, we examined association results for 29 available out of 30 total SNPs from 
22 independent loci known to be associated with CRC from previous studies (Table 2.1). 





. The p-value criterion for genome-wide statistical significance of SNP 




 However, those SNPs with p-values less than 5x10
-7
 but larger 
than 5x10
-8




2.2.5 Replication in MECC and joint meta-analysis 
 To replicate our discovery meta-analysis findings, we used the same logistic regression 
analysis methods described above to examine the marginal association between each SNP with 
p<0.05 from the MECC+CFR discovery meta-analysis and CRC status in an independent set of 
MECC samples. Models were adjusted for age, sex, and 2 PCs. As for the MECC discovery set, 
higher PCs were outlier-driven, so additional adjustment beyond 2 PCs was not conducted. 
Height was also evaluated as a potential confounder given prior data for one of the SNPs that 
arose in our analyses, and was considered after adjusting for these four covariates using a 
change-in-estimate criterion approach
83
. Because it has been demonstrated that joint analysis of 
two-stage GWAS designs is more efficient than replication-based analysis
84
, we also conducted a 
fixed-effects meta-analysis of results with p<0.05 from the discovery MECC/CFR meta-analysis 
with the results from the MECC-based replication. Subsequently, for a region identified as a 
novel, genome-wide significant susceptibility locus, we removed the p<0.05 discovery filter to 
explore associations in the region in more depth through fine mapping. Regional plots of 
association results near the genome-wide significant finding were generated using LocusZoom 




2.3.1 Discovery meta-analysis 
  Pairwise plots of the first 3 eigenvalues for MECC and first 4 eigenvalues for CFR from 
PCA demonstrated that adjustment for the first 3 and 4 PCs, respectively, captured the majority 
of genotypic variability clearly attributable to fine-scale population substructure (Figure 2.2; 
Figure 2.3). Thus, the first 3 and first 4 PCs were selected as covariates for adjustment in MECC 




 The Q-Q plot of p-values from the fixed-effects meta-analysis of study-specific, adjusted 
logistic regression model results shows the rank-ordered observed –log10(p-value) plotted against 
the rank-ordered expected –log10(p-value) (Figure 2.6). The p-values above the diagonal line in 
the upper-right quadrant of the plot demonstrate that there are a number of SNPs with 
associations more statistically significant than expected by chance alone, assuming a uniform 
distribution of p-values. Further, the associated GC λ value of 1.033 suggests that the selected 
covariates and PCs provide reasonable control for population stratification. The Manhattan plot 
displays summary results from the meta-analysis by chromosomal position and highlights a peak 
on chromosome 4 with six loci in tight linkage disequilibrium reaching genome-wide 
significance (Figure 2.7).   
 
Figure 2.6. Q-Q plot of p-values derived from the inverse-variance-weighted, fixed-effects meta-
analysis of adjusted logistic regression model results run on MECC Omni + CFR Illumina 
discovery samples. The MECC analyses were adjusted for age, sex, batch, and 3 PCs. The CFR 





Figure 2.7. Manhattan plot of –log10(p-values) from the inverse-variance-weighted, fixed-effects 
meta-analysis of discovery stage MECC and CFR adjusted association results. Each circle 
represents the –log10(p-value) for one of 9,516,354 SNPs plotted against its chromosomal 
location on the x-axis. Blue line = suggestive line for genome-wide significance at 5x10
-7
. Red 




 rs17042479 was the SNP in the chromosome 4 genome-wide significant region with the 
most significant p-value (risk allele = G; OR per risk allele = 1.67; p-value = 1.5x10
-8
). The 
directions of effect for MECC and CFR were consistent, with CFR exhibiting a slightly 
attenuated effect. Study-specific estimates demonstrate that the result was not heavily driven by 
either MECC or CFR findings, and the average minor allele frequency across studies was 
approximately 10%. This SNP was directly measured in the MECC discovery samples, CFR 
Set1, and MECC replication samples (imputed only in CFR Set 2). The SNP falls about 250 
Kilobases (Kb) upstream of the ~800 Kb gene FSTL5 (follistatin-like 5) and approximately 720 




chromosome 3 reached our suggestive threshold for genome-wide significance of p<5x10
-7
; 
however, the lack of SNPs in LD with trailing p-values (i.e. attenuated association p-values for 
nearby SNPs as LD with the index SNP decreases) suggests that they may be false positive 
results. The complete list of most significant association findings (p<=3x10
-6
) between effect 
allele dosage and CRC status, visually indicated by the inflated tail of observed –log10(p-values) 
in the Q-Q plot (Figure 2.6) and as SNPs above the blue line in the Manhattan plot (Figure 2.7), 
are summarized in Table 2.3. Further, we also demonstrated that 14 out of 29 previously 
identified CRC risk alleles that were imputed with high quality and analyzed in this meta-




Table 2.4). Twenty-six out of 29 known susceptibility markers had a consistent risk allele and 
direction of effect with the previously published result. The most statistically significant risk 








Table 2.3. Summary of SNPs associated with CRC (p < 3x10
-6
) in the discovery MECC + CFR 






































































































411 g 0.10 
FSTL5 
(upstream) 2.08 0.22 
6.0E-
04 1.59 0.10 
3.4E-





957 c 0.10 
FSTL5 
(upstream) 2.08 0.22 
6.0E-
04 1.59 0.10 
3.9E-





405 a 0.10 
FSTL5 
(upstream) 1.89 0.22 
3.7E-
03 1.61 0.10 
1.8E-





404 t 0.10 
FSTL5 
(upstream) 1.82 0.22 
5.3E-
03 1.61 0.10 
1.9E-





215 c 0.10 
FSTL5 
(upstream) 1.82 0.21 
5.5E-
03 1.61 0.10 
2.0E-





693 a 0.10 
FSTL5 
(upstream) 1.85 0.22 
4.9E-
03 1.61 0.10 
2.3E-





191 t 0.10 
FSTL5 
(upstream) 1.72 0.21 
1.1E-
02 1.61 0.10 
2.5E-





379 g 0.09 
FSTL5 
(upstream) 1.72 0.21 
1.0E-
02 1.61 0.10 
2.8E-





140 g 0.90 
LINC00488 
(downstream) 1.49 0.18 
2.6E-
02 1.67 0.11 
1.3E-





255 g 0.10 
FSTL5 
(upstream) 1.72 0.21 
1.1E-
02 1.59 0.10 
4.1E-





299 a 0.07 
FSTL5 
(upstream) 2.22 0.26 
2.0E-
03 1.64 0.12 
3.0E-





755 t 0.92 
RASA2 
(intron) 1.90 0.25 
1.1E-
02 1.57 0.10 
1.1E-





723 g 0.07 
FSTL5 
(upstream) 2.22 0.26 
2.1E-
03 1.61 0.12 
4.5E-





336 c 0.07 
FSTL5 
(upstream) 2.22 0.26 
2.1E-
03 1.61 0.12 
4.6E-





891 c 0.07 
FSTL5 
(upstream) 2.27 0.26 
1.9E-
03 1.61 0.12 
5.5E-





313 a 0.07 
FSTL5 
(upstream) 2.08 0.25 
3.6E-
03 1.61 0.12 
4.1E-





355 g 007 
FSTL5 
(upstream) 2.08 0.25 
3.6E-
03 1.61 0.12 
4.1E-





517 a 0.23 
PDE11A 
(intron) 1.27 0.14 
9.1E-
02 1.45 0.08 
2.7E-





796 c 0.07 
FSTL5 
(upstream) 2.04 0.25 
4.4E-
03 1.59 0.12 
5.5E-





65 a 0.02 
PIK3R1 
(downstream) 0.27 0.32 
4.9E-
05 0.51 0.22 
2.4E-





864 t 0.06 
FSTL5 
(upstream) 2.44 0.29 
2.1E-
03 1.61 0.12 
1.3E-





04 a 0.96 
SYNPR 
(intron) 2.07 0.23 
1.7E-
03 1.85 0.18 
4.7E-
04 1.93 0.14 
2.8E-
06 






Table 2.4. Discovery MECC + CFR meta-analysis association results for previously identified 
risk alleles. SNPs in bold have nominally significant associations with CRC (p<0.05). 
SNP CHR BP 
Locus A1
* 





rs6691170 1 222045446 
1q41 (DUSP10) 
t g 0.37 0.99 0.05 0.84 t 
rs6687758 1 222164948 a g 0.79 1.08 0.06 0.19 g 
rs11903757 2 192587204 2q32.3 (NABP1) t c 0.85 0.82 0.08 
 
0.0097 c 
rs10936599 3 169492101 3q26.2 (MYNN) t c 0.23 0.95 0.06 
 
0.42 c 
rs647161 5 134499092 5q31.1(AK026965) a c 0.69 1.11 0.06 
 
0.070 a 
rs1321311 6 36622900 6p21 (CDKN1A) a c 0.28 1.08 0.06 
 
0.19 a 
rs7758229 6 160840252 6q25.3 (SLC22A3) t g 0.31 1.01 0.06 
 
0.84 t 
rs16892766 8 117630683 8q23.3 (EIF3H) a c 0.89 0.79 0.08 
 
0.0052 c 
rs10505477 8 128407443 
8q24 (MYC) 
a g 0.54 1.21 0.05 
 
0.0003 t 
rs6983267 8 128413305 t g 0.45 0.84 0.05 0.0006 g 
rs7014346 8 128424792 a g 0.40 1.14 0.05 0.012 a 
rs719725 9 6365683 9p24 (TPD52L3) a c 0.62 1.17 0.05 
 
0.0028 a 
rs10795668 10 8701219 
10p14 
(LOC338591) 




rs3824999 11 74345550 11q13.4 (POLD3) t g 0.45 0.86 0.05 
 
0.0040 g 
rs3802842 11 111171709 11q23 (C11orf93) a c 0.70 0.86 0.06 
 
0.0068 c 
rs10774214 12 4368352 12p13.32(CCND2) t c 0.38 1.08 0.05 
 
0.14 t 
rs11169552 12 51155663 12q13.12 (LARP4) t c 0.27 0.86 0.06 
 
0.0081 c 
rs4444235 14 54410919  
14q22.2 (BMP4) 
t c 0.50 0.97 0.05 
 
0.50 c 
rs1957636 14 54560018 t c 0.41 1.08 0.05 
 
0.12 t 
rs16969681 15 32993111 15q13.3 
(CRAC1,HMPS, 
GREM1) 
t c 0.10 1.17 0.09 
 
0.082 t 
rs4779584 15 32994756 t c 0.20 1.12 0.07 
 
0.086 t 
rs11632715 15 33004247 a g 0.48 1.05 0.05 
 
0.34 a 
rs9929218 16 68820946 16q22.1 (CDH1) a g 0.31 1.01 0.06 
 
0.92 g 
rs4939827 18 46453463 18q21 (SMAD7) t c 0.56 1.19 0.05 
 
0.0010 t 
rs10411210 19 33532300 19q13.1 (RHPN2) 
 
t c 0.12 0.91 0.08 
 
0.23 c 
rs961253 20 6404281 
20p12.3 (BMP2) 
a c 0.36 1.13 0.05 
 
0.025 a 
rs4813802 20 6699595 t g 0.66 0.88 0.05 0.014 g 
rs4925386 20 60921044 20q13.33(LAMA5) t c 0.29 0.86 0.06 0.0089 c 
rs5934683 X 9751474 
Xp22.2 
(SHROOM2) 










 Genetic markers from the previously conducted MECC+CFR meta-analysis with p<0.05 
were carried forward into this stage (nmarker = 492,866). The combined meta-analysis of MECC 
discovery and CFR discovery samples together with MECC replication samples demonstrated 
that the region on chromosome 4q32.2 remains statistically significant at a genome-wide 
threshold. In the combined analysis, rs35509282 was the most strongly associated meta-analysis 
finding (risk allele = A; OR per risk allele = 1.54; p-value = 8.2x10
-9
), with the MECC 
replication-specific result consistent in direction with a p-value of 0.033 (Table 2.5). All findings 
with p<5x10
-7
 except for one fell within this region, and the OR estimates and average allele 
frequencies indicate strong LD among all chromosome 4 top hits. Height was evaluated as a 
potential confounder in the MECC replication samples for the top 16 hits in the intergenic 
FSTL5|NAF1 region (Table 2.6). Height was not associated with CRC (Figure 2.8; t=0.78; 
p=0.44), and none of the genotypes were associated with height by linear regression (p-value 
range: 0.56-1.00). Applying a change-in-estimate criterion for ORs of 10%, we showed that 
adjustment for height as a potential confounder in genome-wide logistic regression models above 
and beyond age, sex, and 2 PCs was unnecessary (Table 2.6). One marker on chromosome 18, a 
TA to T deletion, also reached a suggestive p-value of 1.4 x10
-7
. However, this finding is not 
novel as it falls in the previously identified 18q21 locus (intronic region of SMAD7)
50,55
.  







Table 2.5. Top hits from MECC discovery (Omni) + CFR discovery + MECC replication (Axiom) meta-analysis. 































rs35509282 4 163333405 0.09 T A 1.89  3.7E-03 1.61  1.8E-06 1.32  0.13 3.3E-02 1.53  0.07 8.2E-09 
rs11736440 4 163336693 0.09 G A 1.85  4.9E-03 1.61  2.3E-06 1.33  0.13 2.5E-02 1.53  0.07 8.3E-09 
rs9998942 4 163340404 0.09 C T 1.82  5.3E-03 1.61  1.9E-06 1.32  0.13 3.1E-02 1.53  0.07 9.7E-09 
rs57336275 4 163341215 0.91 T C 0.55 5.5E-03 0.62 2.0E-06 0.76 0.13 3.5E-02 0.65  0.07 1.9E-08 
rs17042479 4 163325411 0.91 A G 0.48 6.0E-04 0.63 3.4E-06 0.80 0.12 6.6E-02 0.66 0.07 1.7E-08 
chr4:163325957:D 4 163325957 0.91 CAT C 0.48 6.0E-04 0.63 3.9E-06 0.80 0.12 6.8E-02 0.66 0.07 2.0E-08 
rs12508784 4 163333299 0.06 G A 2.22  2.0E-03 1.64  3.0E-05 1.45  0.16 1.8E-02 1.64  0.09 3.3E-08 
rs11100443 4 163337191 0.09 C T 1.72  1.1E-02 1.61  2.5E-06 1.28  0.13 4.9E-02 1.49 0.07 4.0E-08 
rs12511058 4 163326723 0.94 T G 0.45 2.1E-03 0.62 4.5E-05 0.69 0.16 1.7E-02 0.62 0.09 4.7E-08 
rs17600575 4 163329336 0.94 T C 0.45 2.1E-03 0.62 4.6E-05 0.69 0.16 1.7E-02 0.62 0.09 4.8E-08 
chr4:163338255:D 4 163338255 0.09 GC G 1.72  1.1E-02 1.59  4.1E-06 1.30  0.13 4.3E-02 1.49  0.07 5.0E-08 
rs12645341 4 163337355 0.94 A G 0.48 3.6E-03 0.62 4.1E-05 0.70 0.15 1.8E-02 0.63 0.09 6.7E-08 
rs12650100 4 163330891 0.06 G C 2.27  1.9E-03 1.61  5.5E-05 1.41  0.15 2.6E-02 1.59  0.09 9.3E-08 
rs12642547 4 163337313 0.06 T A 2.08  3.6E-03 1.61  4.1E-05 1.41  0.15 2.5E-02 1.59  0.09 9.3E-08 
rs2122494 4 163331379 0.91 A G 0.58 1.0E-02 0.62 2.8E-06 0.81 0.13 8.9E-02 0.67 0.08 1.1E-07 
chr18:46455468:D 18 46455468 0.43 TA T 1.10 4.1E-01 1.28 4.5E-05 1.27 0.07 5.4E-04 1.25 0.04 1.4E-07 
rs59363334 4 163340796 0.94 T C 0.49 4.4E-03 0.63 5.5E-05 0.72 0.15 3.0E-02 0.64 0.09 1.7E-07 










Table 2.6. Assessment of height as a potential confounder of the most significant SNP-CRC 
associations from the joint meta-analysis.  
SNP A1 A2 FRQ OR* SE* P* OR** SE** P** % change in OR 
rs17042479 A G 0.92 0.80 0.12 0.06 0.78 0.13 0.05 -2.46% 
chr4:163325957:D CAT C 0.92 0.80 0.12 0.07 0.78 0.13 0.06 -2.39% 
rs12511058 T G 0.95 0.69 0.16 0.02 0.68 0.17 0.02 -0.48% 
rs17600575 T C 0.95 0.69 0.16 0.02 0.68 0.17 0.02 -0.54% 
rs12650100 G C 0.95 0.71 0.16 0.03 0.71 0.17 0.04 0.11% 
rs2122494 A G 0.93 0.80 0.13 0.09 0.79 0.14 0.08 -1.77% 
rs12508784 G A 0.95 0.69 0.16 0.02 0.68 0.17 0.02 -1.16% 
rs35509282 T A 0.93 0.75 0.13 0.03 0.74 0.14 0.03 -2.12% 
rs11736440 G A 0.93 0.74 0.13 0.02 0.73 0.14 0.02 -1.92% 
rs11100443 C T 0.93 0.78 0.13 0.05 0.76 0.14 0.05 -1.75% 
rs12642547 T A 0.95 0.71 0.15 0.02 0.70 0.16 0.03 -1.16% 
rs12645341 A G 0.95 0.70 0.15 0.02 0.69 0.16 0.02 -0.85% 
chr4:163338255:D GC G 0.93 0.77 0.13 0.04 0.75 0.14 0.04 -2.08% 
rs9998942 C T 0.93 0.75 0.13 0.03 0.74 0.14 0.03 -2.02% 
rs59363334 T C 0.95 0.72 0.15 0.03 0.71 0.16 0.03 -1.06% 
rs57336275 T C 0.93 0.76 0.13 0.03 0.74 0.14 0.03 -1.98% 
*   Adjusted for age, sex, 2 PCs; ** Adjusted for age, sex, 2 PCs, height  
A1 = allele 1/effect allele for corresponding odds ratio; A2 = allele 2/alternate allele; FRQ = A1 
frequency; SE = standard error; OR = odds ratio 
 
 Because the chromosome 4 and 18 associated SNPs reached genome-wide significance 
and suggestive levels, respectively, we removed the discovery p-value filter of less than 0.05 and 
examined the full 3-study meta-analysis results in these chromosomal locations. Regional 
LocusZoom plots summarize the fine mapping that is accomplishable via 1000G imputation. The 
association finding at 4q32.2 localizes to an approximately 250 Kb region upstream of FSTL5 






 plot of regional association results for the novel 4q32.2 genome-wide 
significant locus (rs17042479 +/- 1Mb). The x-axis represents physical position on chromosome 
4, and the y-axis shows the -log10(p-value) of from the meta-analysis of MECC Omni + CFR + 
MECC Axiom. Each circle represents one SNP’s association with CRC. Purple = index SNP 
(rs17042479). Correlation (r
2
) between the index SNP and each other SNP was calculated based 




 plot of regional association results for the suggestive and previously 
identified 18q21 locus. The x-axis represents physical position on chromosome 4, and the y-axis 
shows the -log10(p-value) of from the meta-analysis of MECC Omni + CFR + MECC Axiom. 
Each circle represents one SNP’s association with CRC. Purple = index SNP (rs7226855). 
Correlation (r
2
) between the index SNP and each other SNP was calculated based on 1000 






 This GWAS meta-analysis with independent replication was designed to identify novel, 
low-penetrance susceptibility loci among sub-populations with European ancestry. In the 
discovery meta-analysis, we identified a novel, genome-wide significant, CRC susceptibility 
locus on 4q32.2 with a MAF of approximately 9%. To date, no other CRC susceptibility loci 
have been identified on chromosome 4. This finding was replicated in an independent set of 
MECC cases and controls with a consistent direction of effect and nominal p-value less than 
0.05. Evidence that known CRC risk loci were also identifiable with our study design 
(combining Ashkenazi Jewish and non-Hispanic whites) increased our confidence in the 
reproducibility and generalizability of this novel finding.  Twenty-six of 29 previously published 
loci replicated with a consistent direction of effect, and for those with inconsistent direction of 
effect or for those not statistically significantly associated at p<0.05, the results might be 
attributed to modest sample size or to differences in LD structure between our sample and other 
samples used in other GWAS. 
 The 4q32.2 region localized based on LocusZoom plots falls approximately 250 Kb 
upstream of the FSTL5 gene. The frequencies of our lead SNPs matched closely with their 
reported MAFs for Europeans from HapMap (CEU) according to the dbSNP database. 
Interestingly, this SNP has a MAF close to 50% for those of Asian and African descent in 
HapMap. Preliminary bioinformatic analysis based on ENCODE
86
 data in the UCSC Genome 
Browser (http://genome.ucsc.edu/cgi-bin/hgGateway) reveals that the broader region around the 
lead discovery SNP (rs17042479) may overlap with an H3K27Ac histone mark (a feature often 
located near active regulatory elements), a DNaseI hypersensitivity region (a chromatin 
accessibility feature common to cis-regulatory sequences), and/or a transcription factor binding 




of genetic variation in this region, it is possible that an intergenic SNP or the genetic element that 
it tags exerts a regulatory effect on the nearest gene, FSTL5. FSTL5 encodes an extracellular 
matrix protein that interacts with metalloproteases and may be structurally similar to some 
collagen-degrading matrix metalloproteinases (MMPs) and MMP inhibitor TIMP1 that are 
critical for normal physiology
87
. Little is known about the gene’s function, but some evidence 
suggests potential links to known etiologic pathways involved in CRC development. In general, 
follistatins bind activins, regulate cellular differentiation, and neutralize TGF-β superfamily 
members (http://www.nlm.nih.gov/cgi/mesh/2011/MB_cgi?mode=&term =Follistatin). The 
TGF-β signaling pathway’s role in CRC development has been clearly characterized.  
 Although there is no literature suggesting a direct role in CRC pathogenesis, genetic 
variation in and expression of FSTL5 have been implicated in association with other complex 
phenotypes. Genetic variation in FSTL5 has been associated with bone marrow suppression 
following thiopurine treatment for inflammatory bowel disease
87
. FSTL5 expression measured 
by immunohistochemistry has been described as a biomarker of poor prognosis in 
medulloblastoma
88
. Among the minimal amount of published literature on the biological 
relevance of this gene and gene region, the NHGRI Catalog of Published Genome-Wide 
Association Studies
89
 has shown effects of markers at 4q32.2 on complex traits, however, on 
completely unrelated phenotypes. An intergenic SNP between FSTL5 and NAF1 has been 
associated with hair morphology
90
. SNPs downstream of FSTL5 have been associated with 
response to amphetamines
91
 and diabetic retinopathy
92
, and an intronic FSTL5 SNP has been 
associated with height
93
 via GWAS. Importantly, we provided evidence that height is not likely 
to confound the genetic marker-CRC associations for our most statistically significant findings 




 Although power calculations would suggest a relatively high probability of identifying 
novel susceptibility loci, the data reveal only a single locus that reaches nominal levels of 
genome-wide significance. Given the selection for cases with a family history of CRC within the 
CFR study, it is possible that this genome wide-signal represents a combination of a low 
penetrance susceptibility allele in the Ashkenazi Jews (MECC) and a higher penetrance, rare 
effect among family history-positive, young age at onset non-Hispanic white (CFR) individuals 
may be driving our result. Further, potential selection bias resulting from CFR case enrichment 
for younger age at onset and family history may have led to overestimates of effect, enabling the 
novel chromosome 4 locus’s detection here but not in previous GWAS. A similar phenomenon 
occurred when the penetrance of BRCA1 and BRCA2 mutations for breast cancer were initially 
overestimated by studies of high-risk families
94
. False positive findings also remain a threat to 
the interpretation of GWAS studies, even when setting a reasonably high threshold for GWAS 
significance. Additional replication studies will help to clarify this possibility. We are currently 
investigating these associations in an additional ~4,500 CRC cases and ~4,500 controls from the 
CORECT study and a new study of 30,000 cases and 15, 000 controls that are planned to be 
studied within the NCI-funded GAME-ON consortium. 
 To determine if this locus has any biological relevance, there are a number of next steps 
to consider. First, fine mapping and screening of coding regions for mutations using standard 
methods offers an advantage to localize the most strongly associated SNPs within the region
95
. 
Next, if justified by fine mapping exercises and more extensive searches of ENCODE data, 
functional work is warranted, leveraging expression quantitative trait loci (eQTL) analyses and 
experimental studies such as chromatin immunoprecipitation and sequencing (ChIP-seq) and 




 While this study has multiple strengths, it is also limited by some of the same 
considerations common to most GWAS studies. First, the assumption that all SNPs conform to a 
log-additive genetic model creates an over-simplified view of the genome. However, it is not 
feasible to identify the appropriate genetic model on a SNP-by-SNP basis for millions of genetic 
markers. Though it is possible to run multiple model forms (recessive, co-dominant, dominant), 
log-additive models were chosen here because they provide a parsimonious approach to the data 
that yield the greatest statistical power while attempting to limit multiple testing. Second, the 
sample size limited our power to detect an effect, and particularly, the power to examine the 
effects of rarer variants either directly measured on the arrays or imputed (MAF < 1%). 
However, it is clear that the combination of Ashkenazi Jewish individuals and non-Hispanic 
whites enriched for family history comprised a unique study sample for detection of a novel 
result. Further, the choice of the non-Ashkenazi Jewish Colon CFR as our second population for 
discovery may decrease the ability to detect significant variants that may be specific to the 
Ashkenazi Jewish founder population.. 
 Finally, multiple levels of control influence the development of a disease phenotype 
including but not limited to known epidemiologic risk factors, sequence variation, transcriptional 
regulation, gene expression, DNA methylation, and chromatin modifications. Here we only focus 
on germline genetic variation, while environmental factors, gene-gene interactions, and gene-by-
environment interactions are known to play roles in the development of CRC. Interactions were 
not the focus here because of the prohibitively large samples sizes needed for their study. In 
addition, GWAS have been criticized for multiple reasons, among which is the inability to 




 As discussed above, next steps including fine mapping of regions with significant hits 
and association studies with cis gene expression will be critical to glean initial insights into the 
function of the genetic region in relation to CRC development. Further, the data from this 
chapter contribute to a larger CORECT consortium effort, which will ultimately have much 
stronger power for revealing common variants with extremely low effect size and 
low/intermediate-frequency variants with larger effect sizes. Each of these variants will have the 
potential to explain some proportion of the missing heritability for CRC. The combined 
contribution of newly-identified susceptibility variants and known risk loci to explaining the 
missing heritability of CRC will be a focus of future investigations using risk modeling. Here, 
we did not calculate the population attributable risk for each suggestive variant, as this parameter 
can be difficult to interpret due to consideration of each factor in isolation without accounting for 




Chapter 3. MicroRNA target site polymorphisms and colorectal cancer risk in the 
Ashkenazi Jewish population 
 
3.1 Introduction 
 In addition to protein-encoding messenger RNAs (mRNAs), other classes of small RNA 
molecules exist with specialized regulatory and processing functions. Among these types of 
regulatory RNAs are microRNAs (miRNAs), short (18-24 nucleotide) non-protein-coding 
molecules that act as post-transcriptional regulators of gene expression
32
. The biogenesis of a 
miRNA begins with transcription from a small, stand-alone gene or an intron or exon of a known 
protein-coding gene and transitions through a series of conversion steps from hairpin precursors 
to duplexed pre-miRNA intermediates, and finally, to mature, single-stranded miRNAs
96,97
. 
MiRNAs exert their regulatory effects via binding to complementary ~6-8 nucleotide target seed 
sites in the 3’ untranslated regions (3’-UTRs) of one or more mRNAs. Depending on the fidelity 
and context of the interaction, this binding acts to repress translation of the messenger into 
protein or to signal for degradation of the targeted mRNA
32,98,99
. Each miRNA typically binds 




 Deregulated miRNA profiles have been described across a range of hematologic 
malignancies and solid tumors including colorectal cancer (CRC)
101,102
. Further, it has been 
suggested by some that miRNA biology can be integrated into the molecular sub-typing of 
colorectal tumors and into the traditional model of genetic alterations accompanying progression 






. As an extension of this work, several miRNAs have 
been proposed as biomarkers for CRC early detection, prognosis, and progression
107-109
.  
 Despite the extensive miRNA profiling in colorectal tumors, the factors driving 
aberrations in miRNA expression and their impact on CRC development remain less clear. One 
hypothesis proposes that single nucleotide polymorphisms (SNPs) found in genes encoding the 
miRNA sequence or 3’-UTR regions of the corresponding binding sites affect miRNA 
transcription, miRNA processing, and/or the fidelity of the miRNA-mRNA interaction. In turn, 
any of these alterations could plausibly impact target mRNA translation into proteins critical for 
cellular differentiation and proliferation. Evidence from studies of candidate miRNA-related 
genetic alterations supports this hypothesis and suggests that such SNPs may alter expression of 
some miRNAs in CRC
110
 and increase or decrease the risk of tumor development
33
. Target site 











; however, replication of these findings has been 
limited with the exception of rs1051690 in INSR and rs17281995 in CD86 
113
. To date, published 
studies have been limited to candidate miRNA-related SNP analyses and have not 
comprehensively investigated polymorphisms implicated in the post-transcriptional miRNA 
regulatory pathway across the genome. 
 In this study, we expanded the search for miRNA-related genetic variants important in 
the etiology of CRC across the genome and investigated the association between thousands of 
genetic variants in miRNA target sites in 3’-UTR regions and miRNA-encoding genes and CRC 
risk using a novel genotyping platform. As opposed to a classical genome-wide association study 
(GWAS) approach which relies on linkage disequilibrium (LD) with haplotype-tagging SNPs, 




specific to the miRNA regulatory pathway. Further, we bioinformatically characterized the 
potential miRNA binding consequences of our most significantly associated SNPs and further 
explored these associations with expression quantitative trait loci (eQTL) analyses. This study 
was designed to evaluate the feasibility of a targeted GWAS approach for identifying lead 
candidates and prioritizing them for functional characterization based on biologically relevant 
hypotheses. The genetically homogeneous founder population of Ashkenazi Jewish individuals 
experiences a high burden of CRC and served as the focus of this study
37
.  
3.2 Materials and methods 
3.2.1 Study population: Molecular Epidemiology of Colorectal Cancer (MECC) Study 
MECC is a population-based, case-control study of pathologically-confirmed, incident 
cases of CRC recruited from a geographically-defined region of northern Israel.  Subject 
recruitment began in 1998 and remains on-going. Individually-matched controls with no prior 
history of CRC are selected from the same source population that gave rise to cases based on the 
Clalit Health Services database. Matching factors include age, sex, Jewish ethnicity (Jewish 
versus non-Jewish), and primary clinic site. Subjects are interviewed to obtain demographic data, 
clinical information, family history, and dietary habits. Also, biospecimens including blood, 
paraffin blocks, and snap frozen tumors are collected. This genome-wide analysis included 
genotype data on 596 cases and 429 controls from MECC (Table 3.1). Case selection for 





Table 3.1. Demographic and clinical characteristics of MECC participants (n=1,025) genotyped 
on the Axiom
®
 miRNA Target Site Genotyping Array platform. 
  Cases (n=596) Controls (n=429) 
Age  [mean(sd)]  70.9 (10.7) 74.3 (10.6) 
Sex (%) 
  Male 291 (48.8) 221 (51.5) 
Female 305 (51.2) 208 (48.5) 
Self-reported race/ethnicity (%) 
  Ashkenazi  595 (99.8) 413 (96.3) 
Ashkenazi/Sephardi  1 (0.2) 4 (0.9) 
Sephardi 0 7 (1.6) 
Ashkenazi/non-Jewish  0 2 (0.5) 
Missing 0 3 (0.7) 
Cancer site (%) 
  Left colon 198 (33.2) - 
Right colon 189 (31.7) - 
Rectum 168 (28.2) - 
Other 33 (5.5) - 
Missing 8 (1.3) - 
Stage at diagnosis (%) 
  I 95 (15.9) - 
II  125 (21.0) - 
III  118 (19.8) - 
IV 48 (8.1) - 
Missing 210 (35.2) - 
 
3.2.2 Genotyping and quality control 
 Germline DNA was extracted from peripheral blood samples and sent to Affymetrix for 
genotyping. Genotyping was conducted using a novel Affymetrix Axiom
®
 miRNA Target Site 
Genotyping array with 237,858 probes (Table 3.2). The chip was originally designed by 
Affymetrix using four different bioinformatic miRNA prediction algorithms, including 
PolymiRTS, dPORE, Patrocles, and microRNA.org. These algorithms were leveraged to select 
polymorphic sites for the array that overlap genes encoding miRNAs, genes encoding proteins 
important for miRNA processing, and/or target seed sites
114-117




panel of ancestry informative markers (AIMs) and loci with known complex trait associations 
from the August 16, 2011 National Human Genome Research Institute (NHGRI) GWAS 
Catalog
118
.  The same MECC samples used in this study were also genotyped on a custom 
Affymetrix Axiom
®
 genotyping platform with ~1.3 million SNPs and indels for a GWAS as part 
of the Colorectal Transdisciplinary (CORECT) Study to compare concordance across the 
genotyping platforms.  
Table 3.2. Variant sources and design of the Axiom
®
 miRNA Target Site Genotyping Array. 
Data provided by Affymetrix. 
Source  Type  Array  
PolymiRTS  
Mature miRNA, processing proteins, miRNA 
hairpin  
440  
Target seed sites  85,900  
dPORE  miRNA gene regulatory regions  10,400  
Patrocles  miRNA genes & target seed sites  1,200  
microRNA.org  Conserved & un-conserved target seed sites  158,400  
Other  
Ancestry Informative Markers  4,470  
Genome-wide association study compatibility  5,010  
Total   237,858  
 
MECC genotype data was cleaned based on quality control metrics at the individual 
subject and SNP levels (Figure 3.1). Samples with >5% missing genotypes, sex mismatches 
(between self-reported and genotypic predicted sex), and duplicate samples were identified and 
subsequently removed. Monomorphic SNPs and those with <95% call rate were excluded as well 
as those inconsistent with Hardy Weinberg Equilibrium (HWE) in controls. Principal 
components analysis (PCA) was conducted on a panel of 4,736 AIMs using the pcaMethods 
Bioconductor package
75,119




confounding due to population stratification. Plots of principal components (PCs) 1-3 on the final 
analysis dataset were generated to examine population structure. Because almost all of the self-
reported Sephardi Jews were controls, making PC adjustment for population structure nearly 
impossible, we eliminated PC-defined non-Ashkenazi Jews in the same way as in Chapter 2. 
 
Figure 3.1. Quality control and filtering pipeline for MECC samples genotyped on the 
Affymetrix Axiom
®
 miRNA Target Site Genotyping Array. PC = principal component. MAF = 
minor allele frequency. 
3.2.3 Gene expression quantification 
 Gene expression levels from 419,473 probe sets derived from two Affymetrix expression 
arrays were quantified on RNA isolated from snap frozen tumors of 331 MECC CRC cases. Of 
these 331 cases, 135 also had high-throughput genotype data available (63 on the Affymetrix 
Axiom
®
 CORECT custom array and 72 on the Illumina HumanOmni 2.5S-v1 BeadChip). 
Methods for gene expression quantification via hybridization to GeneChip
®
 Human Genome 






Briefly, expression was measured in two batches (one for each array) followed by quantile 
normalization and log2 transformation of MAS 5.0-calculated signal intensities. Data from the 
two batches were aligned after individual batch preprocessing and quality control.   
3.2.4 Statistical and bioinformatic analysis 
 Logistic regression was employed to examine the marginal association between each 
marker on the miRNA target site array with MAF>=1% (nmarker = 55,208) and CRC risk 
assuming a log-additive genetic model. Here, each additional copy of the minor allele was 
assumed to confer the same magnitude of risk or protection. Each model was run both unadjusted 
and adjusted for sex, age, and the first two PCs (see parameterization below). We calculated beta 
coefficients, standard errors, odds ratios (OR) with associated 95% confidence intervals, and p-
values from unconditional logistic regression. The Bonferroni-corrected alpha level was set at 
9.0x10
-7
 (0.05/55,406 SNPs). 
Unadjusted:  
  logit[P(CRC)] = β0 + β1*SNP + ε 
Adjusted:  
  logit[P(CRC)] = β0 + β1*SNP + β2*PC1 + β3*PC2 + β4*AGE + β5*SEX +ε 
           where SNP = 0 for AA, 1 for AB, and 2 for BB when B is the minor allele 
   PC1 = value of principal component 1 
   PC2 = value of principal component 2 
   AGE = age at diagnosis (cases) or age at study recruitment (controls) 




After taking this genome-wide approach, we then examined previously published SNPs from 
three studies in the candidate miRNA-related polymorphism literature to assess our ability to 
replicate purported risk loci
33,111,112
.  
 To begin the bioinformatic characterization of functional consequences of our most 
significantly associated SNPs, we  investigated predicted changes in miRNA binding using a 
combination of algorithms: microrna.org, miRBase, PolymiRTS, and dPORE
114,115,119,121-124
.  In 
addition, we conducted analysis of variance (ANOVA) to compare differences in gene 
expression by genotype for all SNPs with association p-values less than 5 x 10
-4
, where 
expression and genotype data permitted. Expression of the gene nearest to each SNP was 
considered.  
3.3 Results 
3.3.1 Targeted genome-wide association analysis 
 The distributions of demographic and clinical characteristics of the final analysis dataset 
were comparable across case and control groups (Table 3.1). Plots of the first 3 eigenvectors 
from MECC PCA indicated that the original samples selected for analysis included some non-
Ashkenazi Jewish individuals (almost exclusively among controls) that inhibited our ability to 
control for confounding due to population stratification through PC adjustment (Figure 3.2). 
Following removal of 5 ethnic outliers and 211 PC-defined non-Ashkenazis, the first 2 PCs were 
sufficient to control for population stratification, as indicated by genomic control lambda (GC λ) 





Figure 3.2. Plots of principal components 1 versus 2 and 1 versus 3 based on 4,736 AIMs from 
the MECC participants genotyped on the Axiom
®
 miRNA Target Site Genotyping Array. 
 Quantile-quantile (Q-Q) and Manhattan plots visually display –log10(p-values) resulting 
from the logistic regression models adjusted for age, sex, and 2 PCs (Figure 3.3). The Q-Q plot 
in the left panel plots the rank-ordered observed –log10(p-value) against the rank-ordered 
expected –log10(p-value). It demonstrates that, on average, we did not observe SNPs with 
associations more statistically significant than expected under a uniform distribution of p-values. 
The GC λ value of 1 suggests that PCs 1 and 2 were sufficient to control for population 
stratification in our ethnically homogenous study sample. The Manhattan plot displays the 
summary results by ordered chromosomal position and shows that our lowest p-values are in the 
10
-5






Figure 3.3. Quantile-quantile and Manhattan plots of p-values for association between each SNP 
and CRC from logistic regression adjusted for sex, age, and 2 PCs. MAF>=1%; nmarker=55,406. 
Genomic control λ = 1. 
 Although none of the individual SNPs achieved genome-wide significance, our top 
findings are detailed in Table 3.3. Interestingly, seven out of our nine most statistically 
significant SNPs yield a predicted change in miRNA binding in an allele-specific manner. Each 
of these seven significant variants predict either a change from no miRNA binding to one or 
more miRNAs binding or from one set of miRNAs to a different set.  None of the most 
significant miRNA SNPs has been previously reported as significantly associated with risk of 
CRC. RAPGEF2 and 4 other nearest genes for SNPs in Table 3.3 were selected for detailed 





Table 3.3. Summary of variants with the most statistically significant associations from the age, 
sex, and PC 1-2 adjusted logistic regression models. A1 miRNA and A2 miRNA refer to 
miRNAs predicted to bind in the presence of each alternative allele. AIM = ancestry informative 
marker. GWAS = GWAS compatibility marker. NA = no prediction available. Grey indicates the 
availability of high-throughput genotype data and gene expression data for the nearest gene. 
rsID CHR BP A1* MAF OR SE** P Gene A1 miRNA A2 miRNA 




















miR-222    
miR-1244  
miR-3129 







rs1834481 11 112023827 G 0.12 0.60 0.14 2.4E-04 IL18 (intron) None 


























































































































































*A1 = effect allele for the corresponding OR; ** SE = standard error of the beta estimate 
 
3.3.2 Gene expression analysis for top association findings 
 Of the top 25 SNPs that met our p-value threshold of 5 x 10
-4 
from the association 
analysis in 3.3.1, 11 corresponding nearest genes had at least 1 matching probe in our gene 
expression dataset. Among the 21 total probes quantifying gene expression from these 11 genes 
(some genes had multiple probes), 13 probes for 6 genes had a corresponding genotype measured 






Table 3.4 enumerates ANOVA results for gene expression [log2(normalized intensity)] by 
genotype for the 6 represented nearest genes with appropriate data availability. The most 
statistically significant intergenic SNP (rs6827968) falls downstream of the RAP guanine 
nucleotide exchange factor 2 (RAPGEF2) gene, with an F statistic of 5.71 and p-value of 0.02. 
RAPGEF2 expression levels plotted against the number of copies of the minor allele at this SNP 
locus in our study sample can be visualized in Figure 3.4. Although rs6827968 is highly unlikely 
to exert a direct regulatory influence via the miRNA pathway on the nearest gene since it is an 
AIM, RAPGEF2 encodes a protein that could plausibly be linked to CRC etiology. RAPGEF2 
activates RAS through promotion of the active GTP-bound state in a GTP/GDP-regulated signal 
transduction switch
125
. This SNP also falls downstream of the follistatin-like 5 (FSTL5) gene. 
Given the genome-wide significance of a SNP in FSTL5 (Chapter 2), we were interested in 
whether or not this miRNA-associated SNP might also lead to deregulation of FSTL5 gene 
expression. However, no corresponding gene expression probe was available in our assay. 




Table 3.4. ANOVA results for gene expression [log2(normalized intensity)] by genotype at top 
SNPs from the logistic regression association analyses between each SNP and CRC status. 
SNP Gene Probe F statistic P 
rs6827968 RAPGEF2 203096_s_at 5.71 0.02 
rs6827968 RAPGEF2 203097_s_at 2.51 0.12 
rs6827968 RAPGEF2 215992_s_at 3.62 0.06 
rs12130051 KIAA0090 212394_at 0.16 0.69 
rs12130051 KIAA0090 212395_s_at 1.60 0.21 
rs12130051 KIAA0090 212396_s_at 0.18 0.67 
rs12130051 KIAA0090 215991_s_at 0.33 0.57 
rs853158 ARHGAP26 205068_s_at 1.51 0.22 
rs853158 ARHGAP26 205069_s_at 0.05 0.82 
rs853158 ARHGAP26 215955_x_at 0.97 0.33 
rs6072275 TOP1 208900_s_at 0.13 0.72 
rs6072275 TOP1 208901_s_at 1.44 0.23 
rs1972820 ERBB4 206794_at 0.07 0.80 
 
Figure 3.4. RAPGEF2 gene expression in colorectal cancers measured by two separate probes in 
72 MECC CRC cases by rs6827968 genotype.   
3.3.3 Replication of previously published risk loci  
 We also examined the CRC association with 19 candidate SNPs previously presented in 
the literature (8 from Landi et al
33
, 5 from Azimzadeh et al
111






which 6 were statistically significant in the original report. In our dataset, we replicated only one 
of the previously reported findings (Table 3.5). The single replicated variant (rs1051690), 
originally reported in Landi et al
33
, falls in the 3’-UTR region of the insulin receptor gene INSR 
(Table 3.5; OR = 1.38; p = 0.03) and has predicted miRNA binding consequences. Although this 
SNP did not meet our association p-value threshold for eQTL analysis, we included it in order to 
provide additional evidence to support prioritization of a replicated locus for functional 
characterization. This SNP provides a clear example of how such a target site polymorphism 








Table 3.5. MECC results from logistic regression adjusted for age, sex, and PC 1-2 for 
previously studied miRNA variants. Data row 1 shows replication of a variant in INSR that was 
suggestively associated with CRC risk in Landi et al
33,113
 (OR (95% CI) = 1.86 (0.99,3.50); 
P=0.052).  















rs1051690* 19 7116963 INSR T 1.86 0.05 1.38 0.15 0.03 
rs1368439* 5 158742014 IL12B G 1.17 0.65 0.80 0.12 0.06 
rs11515** 9 21968199 CDKN2A G 1.16 0.71 1.14 0.12 0.30 
rs1126547*** 3 14186757 XPC C 1.13 0.73 1.14 0.13 0.32 
rs3135500* 16 50766886 NOD2 A 1.22 0.07 1.09 0.09 0.37 
rs1131445* 15 81601782 IL16 C 0.99 1.00 0.93 0.09 0.41 
rs1131445** 15 81601782 IL16 C 2.21 0.00 0.93 0.09 0.41 
rs1051208** 3 12625747 RAF1 T 1.11 0.85 0.90 0.14 0.44 
rs4596*** 11 18388128 GTF2H1 C 0.79 0.03 0.93 0.10 0.44 
rs2229090*** 3 14187345 XPC C 0.91 0.38 1.08 0.12 0.54 
rs17281995* 3 121839641 CD86 C 2.93 0.01 1.05 0.12 0.66 
rs11677* 1 20301964 PLA2G2A T 1.02 0.97 1.06 0.14 0.70 
rs7356*** 1 28218100 RPA2 C 1.33 0.04 1.02 0.09 0.81 
rs1803541*** 2 128014913 ERCC3 T 0.96 0.70 0.97 0.14 0.86 
rs16870224* 5 40692940 PTGER4 A 2.31 0.14 0.99 0.12 0.94 
rs16870224** 5 40692940 PTGER4 A 0.29 0.11 0.99 0.12 0.94 
rs4781563*** 16 14045399 ERCC4 A 0.68 0.09 1.00 0.10 0.97 
rs916055* 17 4534834 ALOX15 C 0.98 0.91 1.00 0.10 0.98 
rs743554** 17 73754248 ITGB4 A 0.76 0.36 NA NA NA 
* Landi et al 2008
33
; ** Azimzadeh et al 2012
111




A1 = effect allele for the corresponding odds ratios; 
++ 






Figure 3.5. INSR gene expression in 135 MECC CRC cases by rs1051690 genotype.  ANOVA 
F-statistic = 21.3 and p-value = 9.0x10
-6
.    
3.3.4 Genotype concordance: miRNA targeted array vs. traditional GWAS array  
 Only 14,436 markers were directly measured on the Affymetrix miRNA Target Site 
Genotyping Array and the CORECT Axiom 1.3M custom array. Among those variants, there 
was a 99.89% overall genotype concordance across arrays. After leveraging imputation to 1000 
Genomes for the CORECT Axiom 1.3M custom array, 63,407 out of 88,205 markers passing 
quality control filters from the targeted array were imputed with high quality. A comparison of 
concordance between the Affymetrix miRNA Target Site Genotyping Array genotypes and 
directly measured and imputed best call genotypes from the CORECT Axiom 1.3M custom array 
showed that the targeted miRNA array has added value over the GWAS array for many markers 
from this regulatory pathway, as heterozygote genotype concordance is severely depressed for 





Figure 3.6. Concordance between directly measured and 1000 Genomes imputed CORECT 
Axiom genotypes and miRNA Target Site Array genotypes in MECC. Best call refers to the 
conversion of genotype dosages from imputation into best genotype calls based on a genotype 
probability threshold of 0.9. Ref. Hom. = reference homozygote; Het = heterozygote. Data 
provided by Affymetrix. 
3.4 Discussion 
 To our knowledge, this is the first study to examine associations between genetic 
variations in miRNA genes or target seed sites and CRC risk using a genome-wide approach 
informed by bioinformatic miRNA prediction algorithms. While we did not identify any 
genome-wide significant associations meeting the traditional threshold of 5x10
-8
, this study did 
highlight suggestive variants with predicted miRNA binding implications. Also, we replicated a 
recent association finding between rs1051690 in INSR and CRC risk and demonstrated 
variability in INSR gene expression by genotype at this locus. While limited with respect to 
power, this pilot study demonstrated the potential for a targeted GWAS approach to identify 
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 Alterations of expression from miRNA targets may be mediated by seed site 
polymorphisms that strengthen or weaken the miRNA-mRNA interaction. We illustrate a 
relevant example in this study from an association finding through eQTL analysis. The INSR 3’-
UTR variant (rs1051690) association with CRC had previously been detected in both Czech 
Republic and Spanish case-control studies assuming a co-dominant model
33,113
. We were able to 
replicate this risk locus based on a log-additive genetic model assumption. Further, in the 
Chapter 2 analysis which included more MECC samples as well as CFR samples, the T allele at 
rs1051690 had a consistent direction of effect (OR=1.11) with a p-value of 0.07. To date, few 
studies have examined the functional consequences miRNA-related SNPs. However, INSR is a 
notable exception. The same group that originally identified the INSR association later conducted 
in vitro luciferase reporter assays to show that the minor allele leads to differential regulation of 
reporter gene expression
113
. Evidence from our eQTL analysis corroborates this finding, and a 
link between insulin resistance and CRC has long been recognized
126
.  It is possible that each 
additional copy of the minor/risk allele reduces miRNA-mRNA binding to the point of inhibiting 
mRNA degradation, which is what may lead to the increased INSR gene expression observation. 
Or, it is possible that the SNP exerts an effect analogous to haploinsufficiency, such that one 
copy of the major allele is not sufficient to appropriately repress INSR protein expression. 
Further functional work is necessary to elucidate this SNP’s mechanism of action.     
 Sethupathy and Collins suggested in 2008 that future studies involved in elucidating the 
role of miRNA-related polymorphisms in complex diseases such as CRC should focus on all 
three of these domains: genetic, functional (testing altered miRNA targeting mediated by genetic 
variation), and mechanistic (testing the mechanism by which altered miRNA leads to tumor 
development)
127




accordance with their recommendations, we also minimize confounding by population 
stratification that limits many candidate gene studies. The next step is to expand our genotyped 
dataset to increase power for detecting novel risk loci. With respect to genotyping platform 
selection for future studies, this chapter highlighted an advantage of this novel genotyping array 
over a traditional GWAS array with imputation based on the 1000 Genomes Project haplotypes, 
particularly when rare variants are of interest. Further, replication and fine-mapping in the 
CORECT Study will strengthen our confidence in both novel and previously published findings. 
Also, functional studies are underway to identify SNP effects on miRNA binding fidelity (for 
rs1051690 as well as other top association findings) and to find the best in vitro model for allele-
specific effects.  
 This study has limitations with respect to power and modeling assumptions. Our sample 
size is limited to only 1,025 samples. However, this analysis, which was able to replicate a 
previously identified miRNA risk locus and characterize preliminary functionality, provides 
justification for study in a larger sample. Our lack of genome-wide significant findings is likely 
to be attributable to a lack of power, and our sample size did not permit the investigation of 
effects for rare variants with MAF<1%. Also, not all SNPs exert their effects according to the 
assumed log-additive genetic model, and this choice made to restrict multiple testing could 
inhibit our ability to identify risk loci that are consistent with a recessive, dominant, or co-
dominant model. Further, we did not consider interactions between these potentially risk-
conferring variants or variant effects in the context of other genetic or environmental risk factors. 
Finally, our ability to examine gene expression was limited by both data availability and 
restriction to studying the SNP’s nearest gene. SNPs in genic or intergenic regions involved with 




 Despite these limitations, we provide evidence that a targeted genome-wide approach for 
studying germline susceptibility can be extended beyond known or purported cancer biology 
pathways to the exploration of a regulatory pathway with widespread post-transcriptional effects. 
A better understanding of the mechanisms by which aberrations in miRNA expression and 
binding impact CRC development and progression may offer critical insights for prevention and 
targeted therapeutic approaches. Specifically, the INSR variant warrants further investigation in a 




Chapter 4. Identification of potentially causal genetic variants for complex congenital heart 
disease through whole-genome sequencing 
 
4.1 Background 
 In the United States, approximately 1 out of every 100 live births is affected by 
congenital heart disease (CHD)
128
. The prevalence rate of complex CHD cases that require 
intensive cardiac treatment and care is estimated to be 2.5 to 3 per 1000 live births
128
. It is 
worthwhile to note that the literature is inconsistent with respect to reporting incidence rate 
versus prevalence rate, and our choice to use the term prevalence rate is consistent with the 
recognition that early fetal loss leads to a potentially major difference in incidence and 
prevalence rates. Further, prevalence estimates of complex CHD lesions among those advancing 
beyond neonates range from 30,0000 to 180,000, depending on an assumption regarding the 
proportion of cases treated
129
. Among the multiple forms of severe CHD, three are the lesions 
relevant to this dissertation chapter (prevalence per million live births): hypoplastic left heart 
syndrome (HLHS, 266 per million), truncus arteriosus (107), and tetralogy of Fallot (407). 
Hypoplastic left heart syndrome (HLHS) is a complex disorder characterized by under-
development of the left ventricle and narrowed or closed mitral and aortic valves
130
. Truncus 
arteriosus is a congenital heart defect typically characterized by an anatomically abnormal 
truncal valve and a ventricular septal defect
131
. Tetralogy of Fallot (TOF) typically consists of 
four anatomical features resulting in low blood oxygenation: a ventricular septal defect, right 
ventricular hypertrophy, pulmonary stenosis, and an overriding aorta. Because we found 




three have the same underlying etiology in the family under study in this chapter. We 
hypothesize that the clustering of these anatomically distinct left-sided and conotruncal lesions 
(truncus arteriosus and TOF) is attributable to a more proximal defect in cardiogenesis. 
 The narrow sense heritability of severe CHD has been characterized for specific lesions 
and estimated to be 99% for HLHS alone or 74% for HLHS with associated cardiovascular 
malformations
14
. Despite the known heritability of CHD, specific genetic risk factors 
contributing to its etiology have remained poorly understood. Chromosomal anomalies, such as 
Turner syndrome, trisomy 13, trisomy 18, DiGeorge syndrome, and Jacobsen’s syndrome 
(terminal 11q deletion) occur in 5-12% of cases
130,132-135
. Also, several critical regions have been 
identified through a recent linkage study of 208 individuals from 33 families with HLHS and 
associated cardiovascular malformations: 6q23.3, 10q22.1, 7q31.2, 11q22.1, 12q13.1, 14q23.2, 
and 20q12
136









. Dozens of other candidate genes for complex 
CHD have been implicated in the recent literature as well
141
. Clearly, multiple genetic loci, 
possibly in combination with established environmental risk factors are implicated in HLHS and 
other forms of complex CHD. These environmental risk factors include, but are not limited to, 
maternal exposures such as maternal rubella, pre-gestational diabetes, phenylketonuria, 
therapeutic and non-therapeutic drugs, and organic solvents
142
. Further identification of risk-
conferring variants and description of the heterogeneous genetic landscape of severe CHD have 
potential to fill in some of the phenotype’s missing heritability, to increase our understanding of 
heart development mechanisms, and to guide the discovery of intervention strategies. It has been 




to left heart hypoplasia; therefore, variants identified in association with HLHS may provide 
insight into genes important for fetal blood flow control and primary heart development
143
. 
Next-generation sequencing technologies, including whole-genome sequencing (WGS), 
hold great promise for enhancing our understanding of the genetic basis underlying complex 
CHD by taking an agnostic approach to identifying genomic variation. NGS refers to a set of 
technologies that use massively parallel sequencing by synthesis to generate thousands to 
millions of short reads (~25-120 nucleotides) with error rates <1%. Paired-end reads are 
reconstructed into a linear sequence of the whole genome by leveraging the human reference 
genome as a scaffold. Benefits of this sequencing approach include profoundly lower per base 
cost of sequencing data as compared to direct Sanger sequencing and the ability to capture novel 
and extremely rare variation that is not typically assessed with SNP genotyping arrays.  
This chapter brings together the rapidly evolving technology of WGS with family-based 
co-segregation analysis to identify rare, potentially causative variants for severe CHD that can 
inform follow-up prevalence studies in cohorts of unrelated individuals. We hypothesize that 
potentially causative genetic variants for complex CHD co-segregating with disease in an 
affected family will be identifiable through WGS and informative regarding candidate genes or 
pathways for future investigations. The index family is particularly unique in that multiple CHD 
cases cluster in a single generation with the same father but different mothers. The implication of 
this methodology, shown by example in this chapter, is that by treasuring your exceptions and 
leveraging informative families, one can narrow the list of candidate disease susceptibility genes 
and pathways to study epidemiologically in larger populations, which can be cost-prohibitive to 





4.2.1 Family recruitment 
The family under study was recruited in 2009 after the proband (IS-1065/SHFG-12005) 
underwent surgical treatment for HLHS. Her two affected half-sisters, one with TOF (SHFG-
12366/CT7-3) and one with truncus arteriosus (SHFG-12463/CT7-4) were also recruited into the 
study. Peripheral blood was drawn from these 3 affected individuals. Later, peripheral blood 
samples were collected from the proband’s unaffected father (CGN-8845-00) in August 2011 
and unaffected full brother (SHFG-23129) in December 2011. The pedigree depicts the presence 
of affected offspring of the unaffected father from two different maternal lineages (Figure 4.1). 
Informed consent was obtained according to Institutional Review Board-approved protocols at 
the Children’s Hospital of Philadelphia and the University of Michigan. 
 
Figure 4.1. Pedigree for the index family affected by complex CHD. Proband is indicated by the 
black arrow. Individuals represented in color had DNA samples available for whole-genome 
sequencing. HLHS = hypoplastic left heart syndrome. 
4.2.2 Whole genome sequence data generation 
 Germline DNA was extracted from the peripheral blood samples of 5 individuals from 
the index family using standard methods (Figure 4.1). Paired-end, whole-genome sequence data 




platforms for germline DNA from 3 affected and 2 unaffected individuals spanning two 
generations of this family. These individuals included the proband with HLHS (III:3); her 
affected half-sisters with TOF (III:2) and truncus arteriosus (III:1), respectively; her unaffected 
full brother (III:4); and their shared, unaffected father (II:7).  
 Initial sequencing included 16 lanes of paired-end reads (120 nucleotides) from the 
Illumina Genome Analyzer II that were run at the University of Michigan (UM) DNA 
Sequencing Core. Sequencing libraries were prepared according to the manufacturer’s 
instructions at UM using the NuGEN Encore™ NGS Library System I.  The proband’s DNA was 
run across 8 lanes, and each of the half-sib’s DNA samples was run on 4 lanes. Because the 
ability to discover single nucleotide variants (SNVs) significantly increases with depth of 
coverage until approximately 15X for homozygous sites and 33X for heterozygous sites, 
additional sequencing depth for the proband and half-sib with TOF was generated on an Illumina 
HiSeq at the University of Southern California
144
. DNA availability for the half-sibling (half-sib) 
with truncus arteriosus was limited and did not permit supplemental sequencing. In addition, new 
sequence data from the proband’s unaffected father and full brother was obtained in order to 
offer new insights about variants segregating in this family. At USC, libraries were prepared 
using the Mondrian SP workstation (NuGen) with NEBNext DNA Library Prep reagents and the 
Mondrian SP Universal cartridge according to the Library Preparation – Method1 protocol.  
4.2.3 Alignment of WGS paired-end reads 
 Sequencing reads were aligned to the human genome reference sequence, followed by 
local realignment around indels and recalibration. A combination of Burrows-Wheeler Aligner 
(v0.6.2) and Picard (v1.71; http://picard.sourceforge.net) were used to globally align paired-end 




duplicate read pairs that commonly arise from PCR amplification of the same original 
fragments
145
. Several tools from the Genome Analysis Toolkit (GATK; v1.6) were employed to 
convert raw aligned reads to analysis-ready reads
146
. Reads were aggregated on a per-sample 
basis into a single binary alignment/map (BAM) file, duplicate reads were removed, and 
remaining reads underwent multi-sample realignment with known sites. Sample-level local 
realignment was accomplished using the RealignerTargetCreator and IndelRealigner tools from 
GATK and was informed by highly confident, known indels from the 1000 Genomes Project 
(1000G) and a 2011 Genome Research publication 2011
79,147
. Following realignment, GATK’s 
Base Quality Score Recalibration (BQSR) was used to adjust quality scores to more accurately 
reflect the probability of read mismatch to the reference. Average depths of coverage across the 
exome and across the genome for each sample were calculated using the GATK 
DepthOfCoverage tool.  
4.2.4 SNP and insertion/deletion (indel) calling and annotation 
 The pipeline developed for SNP and small indel (~10 nucleotides or less) calling was 
modeled after the published GATK pipeline for multiple samples in a cohort, which allows 
variant discovery across samples in the index family
146
. UnifiedGenotyper was run with a 
minimum Phred-scaled (-10log10) confidence score threshold of 20 to account for the range of 
coverage depths across samples and for the filtering steps to follow. Raw variant calls were then 
statistically filtered to remove predicted false positives using the Variant Quality Score 
Recalibrator (VQSR). This tool generated a Gaussian mixture model trained on highly-confident, 
known variant sites from dbSNP, 1000G, and HapMap to determine the probability that other 
sites in our dataset were true. For SNPs, the following annotations were using for training: 




(HaplotypeScore), Mapping Quality Rank Sum Test (MQRankSum), Read Position Rank Sum 
Test (ReadPosRankSum), Fisher’s exact test for strand bias (FS), mapping quality (MQ), and 
depth (DP). For indels, the following annotations were applied: QD, FS, HaplotypeScore, and 
ReadPosRankSum. VQSR added annotations to the “FILTER” field of the variant call format 
(VCF) file, and the user selected the truth sensitivity level at which to start filtering out variants 
based on a balance between likely true and false positives and on the novel transition-to-
transversion (Ti/Tv) ratio. Variants not passing the VQSR filter at the data-driven sensitivity 
level selected were removed using VCFtools
148
 (v0.1.10) prior to co-segregation analyses. 
 Standard variant quality indicators were calculated on the resulting multi-sample VCF 
file, as well as on an individual sample basis, using the GATK VariantEvalWalker. The 
comparison file contained variants from dbSNP build 129, the build just prior to when the 
deposition of 1000G variants began. Quality metrics were checked for consistency with 
expectations. Then, genomic annotations were assigned to each variant, where applicable and 




 (v2.0.5), and GATK’s 
VariantAnnotator. Among these annotations were allele frequency in 1000G European samples, 
gene name, effect type (e.g. frameshift, non-synonymous coding, 3’-untranslated region (UTR), 
synonymous coding, etc.), impact (high impact = splice site acceptor, splice site donor, start lost, 
exon deleted, frameshift, stop gained, or stop lost), SIFT
151
 prediction score, and Polyphen-2
152
 
predictions for variant impact on protein structure and function. PolyPhen-2 and SIFT were 
employed to illuminate potentially damaging variants based on predicted protein structure and 
between-species conservation
151,152
. Variants considered to be potentially damaging were those 
with a SIFT score less than or equal to 0.05 and/or Polyphen-2 prediction outcome of possibly 




dbSNP build 137 to highlight rare variants without minor allele frequency (MAF) >=1% in at 
least one of over 50 major populations (with >=2 two unrelated carrying the minor allele).  
4.2.5 Structural variant identification 
 To provide evidence that larger structural variation commonly driving syndromic CHD 
was not segregating in this family, we ran a Cytogenomic SNP Microarray (Affymetrix 
CytoScan HD
®
 Array) on the proband’s germline DNA in a CLIA-certified laboratory (ARUP 
Laboratories). In addition to clinical genetic testing, we evaluated structural variants that might 




4.2.6 Co-segregation analysis 
 The final SNV and indel variant calls from the parsed, multi-sample VCF were analyzed 
in R for co-segregation according to one of three genetic models that could theoretically be 
consistent with the pedigree under study: 1) autosomal dominant (AD) with incomplete 
penetrance, 2) AD with gonadal mosaicism in the father, and 3) autosomal recessive. Mosaicism 
refers to the existence of two or more genetically distinct groups of cells in a single individual 
that arise following mutation and cell division. If this phenomenon occurs in the sperm cell 
population, a genetic variant passed by a father to his offspring may only be present in the 
contributing subpopulation of his germ cells and undetectable (or below the threshold for 
detection) in his peripheral blood. For the AD model with incomplete penetrance, we considered 
variants that were a) carried with one copy by all 3 affected individuals and the unaffected father 
(initially ignoring the unaffected brother’s genotype) or b) carried with one copy by high-
coverage affected individuals (proband and half-sib with TOF) and the unaffected father 




penetrance needed to be invoked for the father but not necessarily the brother. However, upon 
generation of our final candidate list, an additional assumption was made that the variant was not 
present in the unaffected brother to avoid generating a candidate list of variants shared by the 
entire family. For the AD model with mosaicism, we identified variants with one copy that were 
a) shared by all 3 affected individuals and not shared by the unaffected father or brother 
(genotype calls allowed to be missing) or b) shared by high-coverage affected individuals and 
not shared by the unaffected father or brother (genotype calls allowed to be missing). Finally, for 
the autosomal recessive pattern of inheritance, we aggregated variants with two copies shared by 
the proband and high-coverage affected with TOF that were also present with 1 copy in the 
unaffected father.  In all three scenarios, we allowed for the possibility that a variant may not be 
called even if present in the half-sib with truncus arteriosus due to low sequencing depth of 
coverage. 
 Considering each genetic model separately, we next restricted the respective candidate 
variant lists to markers with MAF<=1% (for AD models) or <=10% (for AR model), and 
subsequently, to those in coding regions. A lenient 10% threshold was selected for the AR model 
because this approximated the expected frequency that would be consistent with the allele 




 + 2pq + q
2
 =1) approximating a disease 
affecting 1 in 100 live births. Rare variants co-segregating according to one of these models and 
predicted to be potentially damaging by SIFT and/or Polyphen-2 were considered causal 
candidates.  
 Further, for each genetic model, we carefully examined variants falling under previously 
identified linkage peaks (6q23.3, 10q22.1, 7q31.2, 11q22.1, 12q13.1, 14q23.2, 20q12) or within 




Table 4.1). We relaxed our allele frequency filters to MAF<=10% for all three models and 
examined each coding variant manually. Resulting SNVs and indels from the genome-wide and 
candidate region analyses for each model were collapsed into a single candidate list of variants 
that could potentially alter gene function but required further validation. For the final variant list, 
an updated version of SIFT and PROVEAN
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 (a new prediction algorithm similar to SIFT but 






Table 4.1. Candidate gene list for complex CHD.  
 
ACTC1 DVL2 GATA6 KIT MYST1 RARA SMAD9 TNNI1 
ACVR1 DYNC1H1 GDF1 KITLG NEUROD1 RARB SMARCD3 TNNI2 
ACVR2B ECE1 GJA1 KRIT1 NF1 RARG SMO TNNI3 
ADAM17 EDN1 GLI2 LBX1 NFATC1 RELA SMYD1 TTC8 
ALDH1A2 EDNRA GLI4 LEF1 NFATC2 RORC SOS1 TTN 
APC EGFR GSC LEFTY1 NFATC3 RXRA SOX4 TWIST1 
APEX1 EP300 GSK3A LEFTY2 NFATC4 RXRB SOX7 TWIST2 
ATP1A1 EPHB2 GSK3B LRRC10 NKX2-5 RXRG SOX9 UGDH 
ATP1A2 EPO HAND1 MAML1 NK3-2 SALL4 SOX10 VANGL1 
AXIN1 ERBB2 HAND2 MAML2 NODAL S1PR2 SOX18 VANGL2 
BBS4 ERBB3 HAS1 MAML3 NOG SEMA3A SRF VCAM1 
BBS5 ETS1 HAS2 MAP3K7IP1 NOTCH1 SEMA3B STIL VCAN 
BBS7 EVX1 HDAC1 MED13L NOTCH2 SEMA3C SUPT5H VEGFA 
BMP1 FGF10 HDAC2 MEF2A NR2F2 SEMA3D SUPT6H VEGFB 
BMP2 FGF4 HDAC3 MEF2B NRG1 SEMA3E TAL1 VEGFC 
BMP4 FGF8 HDAC4 MEF2C NRP1 SEMA3F TAZ WIF 
BMP5 FIGF HDAC5 MESP1 NRP2 SEMA3G TBX1 WNT1 
BMP6 FLT4 HDAC6 MESP2 NTF3 SEMA4A TBX10 WNT10A 
BMP7 FN1 HDAC7 MIB1 NTRK3 SEMA4B TBX15 WNT10B 
BMP10 FOLR1 HDAC8 MIRN1-1 NUMBL SEMA4C TBX18 WNT11 
BMPR1A FOXC1 HDAC9 MIRN1-2 PAX3 SEMA4D TBX19 WNT16 
BNIP3L FOXC2 HEG1 MKKS PCAF SEMA4E TBX2 WNT2 
CACNA1C FOXH1 HEY1 MKL1 PCSK6 SEMA4F TBX20 WNT2B 
CCM2 FOXJ1 HHEX MKL2 PDGFRA SEMA4G TBX21  
CER1 FOXP1 HIF1A MEOX2 PHC1 SEMA5A TBX22  
CFC1 FOXP2 HOPX MSX1 PITX2 SEMA5B TBX3  
CHD7 FOXP3 HOXA3 MSX2 PLXNA1 SEMA6A TBX4  
CHRD FOXP4 HSPG2 MTHFR PLXNA2 SEMA6B TBX5  
CITED2 FURUIN IFT52 MYBPC3 PLXNA3 SEMA6C TBX6  
CREBBP FZD1 IGF1R MYC PLXNA4 SEMA6D TEAD1  
CRELD1 FZD10 IHH MYCN PLXNB1 SEMA7A TEK  
CRKL FZD2 IRX3 MYH6 PLXNB2 SHH TFAP2B  
CSRP1 FZD3 IRX4 MYH7 PLXNB3 SMAD1 TGFA  
CTNNB1 FZD4 ISL1 MYL2 PLXNC1 SMAD2 TGFB1  
CXADR FZD5 ISL2 MYL3 PLXND1 SMAD3 TGFB2  
DHFR FZD6 JAG1 MYL4 PSEN1 SMAD4 TGFB3  
DKKL1 FZD7 JUN MYL7 PTK2 SMAD5 TGFBR1  
DLC1 FZD9 KDR MYLK2 PTPN11 SMAD5OS TGFBR2  
DLL1 GATA4 KHDRBS1 MYLK3 PTPN21 SMAD6 TGFBR3  




4.2.7 Sanger sequencing 
In our initial analysis, we attempted to validate all variants that co-segregated according 
to one of our 3 pre-specified genetic models and that met the genome-wide filtering criteria 
described in 4.2.6. The goal was to validate variants using a technique independent of NGS to 
eliminate false-positive results and yield a list of genes and/or pathways to carry forward into 
future functional and population-based studies. Primer sets were designed for polymerase chain 
reaction (PCR) amplification of the 28 identified regions of interest. We attempted to validate ten 
variants by Sanger sequencing first in the half-sib with truncus arteriosus prior to moving onto 
the whole sample set, as calls were absent for this individual (likely due to low coverage). For 
another 18 variants, direct sequencing was conducted in either the proband and half-sib with 
truncus arteriosus or the full complement of 5 samples.  
4.2.8 Quality control 
 We employed quality control (QC) methods to verify sample purity represented in our 
sequencing reads and to rule out the presence of sample contamination. The VerifyBamID tool 
was employed to detect whether reads in a given indexed BAM file were actually generated 
based on reads from a mixture of more than one individual sample
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. The tool’s FreeMix 
parameter measured the percent contamination in a BAM file, with greater than or equal to 0.03 
serving as the threshold for evidence of contamination. 
4.2.9 Sequencing quality and contamination 
 After completion of the full analysis pipeline, including attempts to validate by Sanger 
sequencing, we detected consistent signs of variant call discrepancies across sequencing 
methods. Although validation rates for NGS are typically low, the validation of some WGS-




sample contamination or swap. Further, identity by descent (IBD) estimates calculated using 
VCFtools and PLINK
81
 indicated that the relationships between individuals according to 
genotype data were not consistent with the verified pedigree. For example, the proband and half-
sib with TOF appeared to be more consistent with full-siblings instead of half-siblings. The 
VerifyBamID FreeMix estimates for all reads aggregated according to their initial sample 
assignment indicated the presence of read contamination in the half-sib with TOF (Table 4.2). 
Each individual lane generated for the half-sib with TOF was subsequently investigated, but 
FreeMix estimates indicated no within-lane contamination from a second sample (Table 4.3). All 
4 lanes from the GA-II when considered together were uncontaminated (FreeMix = 0.0082), and 
all 3 lanes from the Hi-Seq when considered together were uncontaminated (FreeMix = 0.0031). 
However, based on clues from IBD analysis and Sanger sequencing results on select variants 
with apparent swaps, we combined GA-II lanes from the TOF half-sib with Hi-Seq lanes run on 
the “unaffected brother”, yielding no contamination (FreeMix = 0.0053). Thus, we concluded 
that the sample labels were swapped between these two individuals when supplementary 
sequencing at USC was completed. We later confirmed with the sequencing facility at USC that 
this bioinformatically-identified sample swap had indeed occurred in the lab but had not been 
reported to our group. After the sample mislabeling issue was discovered and reads from the 
appropriate lanes were reassigned to the correct individuals, the full pipeline from 4.2.3 through 
4.2.6 (with the exception of alignment) was re-run, and the results presented below are based on 





Table 4.2. VerifyBamID FreeMix estimates for each individual with WGS reads combined 
across sequencing lanes. 
Sample – data combined across lanes  FreeMix  
Proband (HLHS) 0.0060  
Unaffected father  0.0028  
Unaffected brother  0.0031  
Half-sib (truncus arteriosus)  0.0079  
Half-sib (TOF)  0.2565  
 
Table 4.3. VerifyBamID FreeMix estimates for each lane of WGS reads generated for the half-
sib with TOF. GA-II/UM = Illumina Genome Analyzer II/University of Michigan. Hi-Seq/USC 
= Illumina Hi-Seq/University of Southern California. 
Lane  Sequencing 
Platform/Center  
FreeMix  
1  GA-II/UM  0.0066  
2  GA-II/UM 0.0106  
3  GA-II/UM 0.0076  
4  GA-II/UM 0.0069  
5  Hi-Seq/USC  0.0034  
6 (failed lane) Hi-Seq/USC  NA  
7  Hi-Seq/USC 0.0033  
8  Hi-Seq/USC 0.0035  
 
4.3 Results 
4.3.1 WGS data summary 
 Paired-end WGS reads were generated for the proband with HLHS (total average depth 
of genome coverage ~36X); her affected half-sisters with TOF (~38X) and truncus arteriosus 




(~33X). When considering data from both platforms combined, average depths of coverage 
across the exome and across the genome for each sample were calculated using GATK’s 
DepthOfCoverage tool (Table 4.4)
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. 
Table 4.4. Whole-genome sequence data summary for a family affected by complex CHD. % of 
reads aligned refers to the percentage of all generated reads per sample that were successfully 






Total # of reads 





Proband  Affected 
(HLHS) 





















Unaffected HiSeq 929,212,340 
(91.6%) 
24.07 29.57 




4.3.2 Variant summary: SNVs, indels, and structural variants 
 The number of variant calls across four novel false-discovery rate levels resulting 
from VQSR filtering was examined, and a truth sensitivity level of 99% was selected for 
generating the final variant call set. This decision was made to limit false positives and to 
match the novel Ti/Tv ratio as closely as possible to our expectations for WGS data (Figure 
4.2). A summary of VQSR-filtered variant calls suggested high concordance with variants 
in dbSNP build 129, Ti/Tv ratios near the expected 2.1 level for WGS data, and 















Table 4.5). Between 4.1 and 4.2 million variants were present in each individual sample, with the 
exception of the half-sib with truncus arteriosus who had fewer calls (~3.7 million). This was 
anticipated due to lower sequencing depth. As expected, the number of variants identified 
declined with increasing chromosome number, corresponding to cytogenetic ordering of the 
autosomes by size (example for proband in Figure 4.3).  
 
Figure 4.2. Tranche (or truth sensitivity)-specific results from variant quality score recalibration. 
X-axis = Total number of novel variants called. Y-axis: novel Ti/Tv ratio and overall truth 
















Table 4.5. SNP and small indel summary for the overall multi-sample VCF and for the per 
individual call sets.  
Sample  Called Loci  Concordance 





Multi-sample  5,776,723  
(4,619,827 SNPs; 916,577 indels)  
96.27%  2.13  1.77  
Proband  4,212,911 
(3,254,953 SNPs; 724,353 indels)  
95.28%  2.13  2.01  
Half-sib (TOF)  4,159,646 
(3,198,101 SNPs; 726,254 indels)  




(3044213  SNPs; 467,835 indels)  
96.25%  2.12  1.33  
Unaffected brother  4,180,504 
(3,201,208 SNPs; 742,436 indels)  
95.2%  2.14  1.85  
 
Unaffected father  4,144,233 
(3,167,282 SNPs; 739,814 indels)  
95.17%  2.14  1.83  
Concordance rate = the percentage of variants with a matching alternate allele when the locus is shared between the 
file under evaluation and the comparison file from dbSNP. Ti/Tv ratio = transition-to-transversion ratio. HetHom 






Figure 4.3. Total number of SNVs and indels identified by chromosome for the proband with 
HLHS. 
 
After filtering based on truth sensitivity level, there were a maximum of 2,508,045 shared 
variants between all three affected offspring (Figure 4.4). The proportion of all variants 
that were novel or rare (MAF<=1%) ranged from 2.4% to 5.3% across the three 












Table 4.5 because variants from unlocalized sequences (i.e. “GL” variants with no 





Figure 4.4. SNVs and indels shared by three affected individuals with severe CHD. Rare = novel 
or MAF<=1%.  
 In terms of structural variation, cytogenomic SNP microarray test results on the proband 
showed no clinically significant chromosomal abnormalities. Due to DNA quality issues, no 
deletion calls <100kb or duplication calls <400kb were made. BreakDancer results were 
uninformative.  
4.3.3 Co-segregation analysis 
Ignoring genotypes from the low-coverage, half-sib with truncus arteriosus, we visualized 
sharing of more confident variant calls in the remainder of the family (Figure 4.5). Red stripes 
represent potentially causative variants that co-segregate according to an AD model with 
incomplete penetrance (i.e. shared by high-coverage affecteds and the unaffected father but not 
the unaffected brother). Purple stripes denote potentially causative variants that co-segregate 
according to an AD model with gonadal mosaicism (i.e. shared by high-coverage affecteds but 





Figure 4.5. Visualization of SNVs and indels that follow AD patterns of inheritance. Red = AD 
with incomplete penetrance. Purple = AD with gonadal mosaicism. Rare = novel or MAF<=1%. 
 When considering variants segregating according to an AD model with incomplete 
penetrance in the father, we initially identified nearly 3 million candidate variants (Figure 4.6). 
However, this number was reduced to less than 500,000 when a stringent MAF filter of 1% was 
applied. Only about 0.6% of these remaining variants fell in coding regions, and among those, 
approximately 2.8% were predicted to be damaging. 
 
Figure 4.6. SNVs and small indels co-segregating with disease according to an autosomal 
dominant genetic model with incomplete penetrance. * = in at least 1 of over 50 major 
populations in dbSNP with at least 2 individuals carrying the minor allele or in HapMap 


















 When restricting the analysis to previously identified linkage peaks and candidate genes 
but with a relaxed variant frequency filter, the analysis yielded an additional 399 variants falling 
in coding regions. This list of 82 potentially damaging variants plus 399 candidate region 
variants was further reduced by eliminating overlap between these two lists, removing variants 
present in the unaffected brother, and filtering out variants present with two copies. If the variant 
is sufficiently rare to cause this rare phenotype in an AD fashion, it is unlikely to be seen twice in 
the same individual. 
 Examining variants that segregate with CHD according to an AD model with gonadal 
mosaicism in the father, we observed 57,514 variants shared by the high coverage affecteds but 
absent in the unaffected family members (Figure 4.7). Only about 6,000 SNPs and indels were 
novel or rare, and of these, 30 fell in coding regions. None of these variants were predicted to be 
damaging by SIFT and/or Polyphen-2. Because none were predicted as damaging, we considered 
all coding variants co-segregating according to this model as potential candidates. When we 
relaxed the frequency filter and examined previously identified candidate regions, the analysis 
yielded an additional 10 variants falling in coding regions. The list of 30 coding variants plus 10 
candidate region variants was further reduced by eliminating overlap between these two lists and 
variants present with two copies in a single individual. 
 
Figure 4.7. SNVs and small indels co-segregating with disease according to an autosomal 
dominant with gonadal mosaicism model. * = in at least 1 of 50 major populations with at least 2 
Shared by 
proband (HLHS) 
+ half-sib (TOF) 













individuals with the minor allele or in HapMap European samples from Utah. **Unaffected 
brother and father were allowed to have missing calls.  
 An autosomal recessive pattern of inheritance was the final genetic model considered. 
Approximately 900,000 variants had two copies of the alternate allele in high-coverage affecteds 
and 1 copy of the alternate allele in the unaffected father (Figure 4.8). After applying MAF and 
coding region filters, there were 120 unique variants that were predicted by SIFT and/or 
Polyphen-2 to be possibly or probably damaging. When restricting the analysis to published 
linkage peaks and candidate genes, 157 more variants falling in coding regions were identified. 
The list of 120 potentially damaging plus 157 candidate region variants was further reduced by 
eliminating overlap between these two lists, removing variants present in the unaffected brother, 




Figure 4.8. SNVs and small indels co-segregating with disease according to an autosomal 
recessive model. * = in at least 1 of 50 major populations with at least 2 individuals with the 
minor allele or in HapMap European samples from Utah. **Unaffected brother and father were 
allowed to have missing calls. 
 
 The final summary of all 32 co-segregating variants across the three genetic models is 
compiled in Table 4.6. This table assumes that the low-coverage, half-sib with truncus arteriosus 
either has a genotype call that’s consistent with the genetic model of interest or a missing call. Of 
these 32 variants, 8 were predicted to be damaging by at least 1 of the 3 algorithms employed. A 
Shared with 2 
copies by 














secondary list of candidate variants can be found in Table 4.7, where variant calls for only the 
low-coverage, half-sib with truncus arteriosus do not fit with the specified genetic model. While 
not of primary interest, these variants could also be critical contributors to the list for validation, 
as our call set for this individual is relatively unreliable. In both tables, a variant on the X 
chromosome appeared to segregate according to an autosomal dominant model with mosaicism. 
In the case of rs201522041 (Table 4.6), this is because the alternate allele was called to be 
present with one copy for the proband (female) and half-sib with TOF (female), with two copies 
for the half-sib with truncus arteriosus (female), and with zero copies for the unaffected father (a 
call was missing for the unaffected brother). For rs2230488 (Table 4.7), the proband and half-sib 
with TOF were called to have one copy of the variant allele, whereas the half-sib with truncus 







Table 4.6. Summary of potentially causative SNVs and small indels co-segregating according to an autosomal dominant (AD) or 
autosomal recessive (AR) model. Variants in red are predicted to be damaging by SIFT, PROVEAN, and/or Polyphen-2 (PP2).  
CHR POSITION Variant REF ALT 
CEU 






rs146554621 GAATA G 0.00 C1orf64 3'-UTR NA NA NA AD mosaicism No 
1 109465165 rs35029887 ACTT A 0.00 GPSM2 DELETION NA N,N,D NA AD mosaicism No 
1 152975715 rs63405761 C T 0.00 SPRR3 SYN 1 N NA AD mosaicism No 
1 172502479 rs2285144 T C 0.00 C1orf9 SYN 1 N NA AD mosaicism No 
2 161350080 . C T NA RBMS1 START GAIN NA NA NA AD mosaicism No 
3 30656065 rs56402737 C T 0.08 TGFBR2 START GAIN NA NA NA AD mosaicism Yes 
3 125286291 . A C NA OSBPL11 NON SYN 0.006 N P AD inc pen No 
6 117622233 rs529038 C T 0.00 ROS1 NON SYN 0.28 N B AD mosaicism No 
8 22570773 . AT A NA PEBP4 3'-UTR NA NA NA AD mosaicism No 
10 70101417 rs16925347 G C 0.09 HNRNPH3 NON SYN 0.41 N B AD inc pen Yes 
10 70405541 rs72799515 A G 0.04 TET1 NON SYN 0.001 N B AD inc pen Yes 
10 70856963 rs67852477 C G 0.01 SRGN NON SYN 0.12 D NA AD inc pen Yes 
10 72520738 rs16927931 G A 0.05 ADAMTS14 3'-UTR NA NA NA AD inc pen Yes 
10 72520835 rs41278004 C T 0.09 ADAMTS14 3'-UTR NA NA NA AD inc pen Yes 
10 73059104 rs74761108 G A 0.03 UNC5B 3'-UTR NA NA NA AD inc pen Yes 
10 73059407 rs58848310 C CT NA UNC5B 3'-UTR NA NA NA AR Yes 
10 73062534 rs2275578 A G 0.03 UNC5B 3'-UTR NA NA NA AD inc pen Yes 
11 58949518 . C T NA DTX4 NON SYN 0.002 N P AD inc pen No 
11 60567525 rs71997819 CCTGGG C 0.00 MS4A10 3'-UTR NA NA NA AD mosaicism No 
11 61908440 rs2277283 T C 0.00 INCENP NON SYN 0.03 D P,D,D AD inc pen No 
11 89608808 . GC G NA TRIM64B FRAME SHIFT NA NA NA AD mosaicism No 
13 37420610 rs146502953 CAA C NA SMAD9 3'-UTR NA NA NA AD inc pen Yes 
15 96881264 rs34353956 C CAACA NA NR2F2 3'-UTR NA NA NA AD mosaicism Yes 
16 50267603 rs11319165 TA T 0.00 PAPD5 3'-UTR NA NA NA AD mosaicism No 
19 36435928 rs79027052 GC G 0.00 LRFN3 3'-UTR NA NA NA AD mosaicism No 
19 40882548 . G A NA PLD3 NON SYN 0.17 N P AD inc pen No 
19 44006360 . C G NA PHLDB3 NON SYN 0.06 N P AD inc pen No 
19 45316804 rs3810141 C T 0.00 BCAM SYN 1 N NA AD mosaicism No 
19 50045878 rs34654230 C T 0.00 RCN3 NON SYN 0.02 D B AD inc pen No 
21 43805637 rs2839501 C T 0.00 TMPRSS3 SYN 1 N NA AD mosaicism No 
22 19748690 rs72646953 G A 0.02 TBX1 SYN 1 N NA AD mosaicism Yes 
X 84343215 rs201522041 TATAA T 0.00 APOOL 
SPLICE SITE 
ACCEPTOR NA NA NA AD mosaicism No 
Missing ID = variant has MAF <1% in all dbSNP populations. REF = reference allele. ALT = alternate allele. CEU MAF = minor allele frequency in CEPH Utah 
HapMap samples. SIFT = updated SIFT scores where <0.05 indicates a damaging prediction. PROVEAN: N = neutral, D = damaging. PP2: D = probably 







Table 4.7. Summary of potentially causative SNVs and small indels co-segregating according to an autosomal dominant (AD) or 
autosomal recessive (AR) model without consideration of half-sib with truncus arteriosus’ genotype due to low depth of coverage. 
Variants in red are predicted to be damaging by SIFT, PROVEAN, and/or Polyphen-2 (PP2). 
CHR BP Variant REF ALT 
CEU 





1 100376325 rs12043139 G A 0.00 AGL NON SYN 0.07 N B,B,B AD inc pen No 
1 119427467 rs61730011 A C 0.09 TBX15 NON SYN 0.02 D NA AD inc pen Yes 
2 65299330 rs141499084 T A 0.01 CEP68 NON SYN 0.01 N P AD inc pen No 
2 128389835 rs190699169 G A 0.00 MYO7B NON SYN 0.005 D B AD inc pen No 
2 131218821 . TC T NA POTEI 3'-UTR NA NA NA AD mosaicism No 
2 140989650 
rs200444225 
rs150474267 GTTC G 0.00 LRP1B 3'-UTR NA NA NA AD mosaicism No 
2 179418318 . T C NA TTN NON SYN 0.39 D B AD inc pen Yes 
2 179549131 rs116676813 C T 0.04 TTN NON SYN 1 N B AD inc pen Yes 
2 206641239 . TCGCA T NA NRP2 FRAME SHIFT NA NA NA AD inc pen Yes 
2 206641245 rs200483574 T TA 0.00 NRP2 FRAME SHIFT NA NA NA AD inc pen Yes 
3 195453017 rs144288174 GC G 0.00 MUC20 FRAME SHIFT NA NA NA AD mosaicism No 
4 36068192 . TA T NA ARAP2 3'-UTR NA NA NA AD mosaicism No 
5 115811273 rs17432496 C T 0.06 SEMA6A NON_SYN 0.47 N NA AD inc pen Yes 
5 178510271 rs147516432 GAT G 0.00 ZNF354C 3'-UTR NA NA NA AD mosaicism No 
6 135523805 . C T NA MYB NON SYN 0 N NA AD inc pen Yes 
6 137519097 rs55665036 C A 0.00 IFNGR1 3'-UTR NA NA NA AD inc pen Yes 
8 28428141 . CA C NA FZD3 3'-UTR NA NA NA AD inc pen Yes 
10 72015573 rs3812694 T G 0.08 NPFFR1 NON SYN 0.006 D D AD inc pen Yes 
11 27517042 . CA C NA LIN7C 3'-UTR NA NA NA AD mosaicism No 
11 56019973 . G T NA OR5T3 NON SYN 0 D D AD inc pen No 
13 28499583 rs139276646 
CCCCT 
CCTCT C 0.00 PDX1 3'-UTR NA NA NA AD mosaicism No 
13 37419247 rs57525591 GTGTGTA G NA SMAD9 3'-UTR NA NA NA AD mosaicism Yes 
14 23999627 rs35092523 TA T 0.00 ZFHX2 FRAME SHIFT NA NA NA AD mosaicism No 
16 338189 rs34015754 C T 0.02 AXIN1 NON SYN 0.12 N P AD inc pen Yes 
19 11459665 rs78738753 G GA 0.00 CCDC159 FRAME SHIFT NA NA NA AD mosaicism No 
19 17932190 rs1047233 T C 0.00 INSL3 SYN 1 N NA AD mosaicism No 
19 35785147 rs56138004 C T 0.00 MAG SYN 1 N NA AD mosaicism No 
20 3627840 rs11481874 C CA 0.00 ATRN 3'-UTR NA NA NA AD mosaicism No 
X 20204461 rs2230488 G T 0.00 RPS6KA3 SYN 1 N NA AD mosaicism No 
Missing ID = variant has MAF <1% in all dbSNP populations. REF = reference allele. ALT = alternate allele. CEU MAF = minor allele frequency in CEPH Utah 
HapMap samples. SIFT = updated SIFT scores where <0.05 indicates a damaging prediction. PROVEAN: N = neutral, D = damaging. PP2: D = probably 





This dissertation chapter presented an initial exploration into the genetic etiology 
underlying severe CHD in a multiplex family affected by both HLHS and conotruncal lesions. 
We leveraged WGS on affected and unaffected family members to examine the potential for a 
rare mutation in a single gene to co-segregate with three anatomically distinct CHD phenotypes. 
The heterogeneous etiologic landscape contributing to CHD development remains under-
characterized, and by studying this family in depth, we had the opportunity to investigate the 
hypothesis that some cases could be driven by a rare variant of large effect in a gene important 
for early cardiogenesis. While the population-wide heritability of complex CHD is high, this fact 
is less relevant for a pedigree with clear evidence for familial clustering and a strong genetic 
component. If a single variant is indeed responsible for disease in this family, that gene, gene 
product, or regulatory element would deserve attention as an important component in the process 
of heart development prior to separation of the left and right chambers. The goals of this study 
were two-fold: 1) to generate a list of candidate variants that may be responsible for CHD in this 
family, and 2) to provide proof of principle that this study design has potential to highlight genes 
and/or pathways for study of these phenotypes at the population level.  
This study identified a list of 32 variants in 29 genes that might contribute to the genetic 
landscape underlying severe CHD etiology for follow-up studies at the bench and in an 
epidemiologic setting. This list includes another 29 variants in 27 genes if flexibility in 
genotypes called for the low-coverage affected with truncus arteriosus was allowed. In 
generating this list of co-segregating variants, we considered the possibility of three genetic 
models that were consistent with the pedigree. Whether or not CHD in this family is driven by 
variation at a single locus remains to be determined, but if it is, the most plausible pattern of 




a causal variant would have to be carried by two unrelated mothers and the father; nonetheless, it 
is a theoretically viable model that deserved attention. Among SNVs and indels in the variant 
lists generated, the most plausible functional candidates are those co-segregating according to 
one of the two AD models and those predicted to be damaging by at least one bioinformatic 
algorithm. Further, although 3’-UTR and synonymous coding variants still have the potential for 
impactful functional consequences, frame shift and non-synonymous coding variants would have 
undeniably simpler interpretations in relation to affecting gene expression and/or protein 
function. Regardless of these speculative criteria for prioritization, all 61 of them are viable 
causal candidates. It is important to note that only a handful of these variants have been 
previously implicated in heart development pathways. This finding was encouraging, indicating 
that we have prioritized several novel genes and/or pathways for CHD development by studying 
this family.  
Ultimately, we generated a candidate list that is too large to individually validate variants 
with extremely limited DNA resources for key affected family members, and family dynamics 
preclude additional sample acquisition. We have not yet validated any of these variants by 
Sanger sequencing or another array-based technology due to limitations regarding DNA sample 
availability. Some resources were exhausted through Sanger sequencing in our original analysis 
that highlighted a sample swap problem. The proband with HLHS is now deceased, and 
additional DNA from the two affected half-siblings is not available. Thus, the remaining 
resources are precious even after whole genome amplification, and additional strategic 
conversations need to take place to optimize DNA usage for validation and functional studies 




Next steps in addition to variant validation on an independent platform include both 
quantitative and experimental approaches. First, we have existing Illumina 550K genotype array 
data on several hundred unrelated individuals with these three phenotypes as well as healthy 
controls. Leveraging imputation to 1000G, we have the potential to conduct prevalence and case-
control association studies to examine if these variants also exert effects on severe CHD in a 
population context. However, a limitation is that many of these variants are quite rare; a vast 
majority were not directly measured on this platform, and high quality imputation will likely be 
difficult. Also, it is possible that the same variant would not be responsible for disease in other 
families or in the general population. Because variants may not be captured on commercially-
available arrays or imputable with high quality, a second option is to directly measure these 
variants using a TaqMan
®
 type of approach or to sequence the full genes including upstream and 
downstream areas to scan for variants in additional cases. Because of the potential for allelic 
heterogeneity in the general population, it will probably be most fruitful to perform targeted 
sequencing of these genes. In addition to likely underpowered single variant association tests, it 
may be worthwhile to consider gene-level association tests like the sequence kernel association 
test
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 to examine the joint of effects of rare variation across pre-specified regions. An 
experimental approach under consideration is the use of morpholinos in zebrafish to knock down 
each individual gene’s function from our candidate list and to screen for developmental cardiac 
phenotypes. 
An apparent limitation to our study is that we focused our efforts solely on Mendelian 
models, concentrating on an analytic strategy including coding regions of the genome. This 
approach may be over-simplified, since regulatory regions of the non-coding genome may also 




multiple genetic and environmental factors contributing to CHD development. It is possible that 
none of the identified variants will replicate in other patients or populations, reflecting either 
biological truth of a family-specific cryptic mutation, methodological limitations, or genetic 
locus heterogeneity. Complex CHD in this family could be driven by a constitutional 
epimutation (heritable gene expression silencing), gene-gene interaction, or gene-environment 
interaction that is not measurable using this study design. Environmental influences are less 
likely to be primary contributors since the heart defects manifest at birth, and the affected 
offspring were born to two unrelated mothers with different prenatal environments. One might 
also speculate that there could be some link between the three severe CHD phenotypes and 
muscular dystrophy in the father’s side of the family; however, there is no literature to date that 
supports an association between these two disease phenotypes, and we did not detect any 
mutations in genes responsible for muscular dystrophy in any patient with CHD.  
Further limitations relate to variant calling and the technical aspects leading to generation 
of our final candidate list. NGS technologies remain notorious for higher error rates than 
traditional Sanger sequencing unless the depth of coverage is overwhelming, so one must rely on 
bioinformatic algorithms to predict false-positivity based on sequence quality metrics. Variant 
calling is a probabilistic science that depends on sequencing quality, depth of coverage, estimates 
of the per base mutation rate, and many other factors. The accuracy of calls increases with 
increasing coverage, but the number of calls is highly sensitive to parameter settings in the 
realignment and recalibration steps of the pipeline. Different variant calling pipelines could yield 
quite different final variant lists for validation. Thus, it is possible that a limited number of the 




In addition, our search for potentially causative variants may have been narrowed by first 
running a linkage analysis in this family. This approach would have highlighted specific regions 
to focus our variant search, but the index family did not have enough informative meioses to 
make the dedication of previous DNA resources to a linkage chip justifiable. However, as an 
alternative, we did leverage previously published linkage peaks and candidate genes to inform 
our variant search. Finally, our main focus, with the exception of the clinical cytogenomic 
microarray, was on variants in coding, or “gene”, regions. However, we know from candidate 
gene and genome-wide association studies that a vast majority of disease-predisposing alleles do 
not fall in these regions but in other sequences with regulatory implications. Ignoring the 
remainder of the genome which was measured via WGS is a key limitation. The literature 
surrounding methods to mine the rest of the genome for potentially functional variants is 
evolving and serves as a future direction of this study. 
 Insights derived from the present analysis have suggested a number of previously 
unrecognized candidate genes and mutations that may be causally related to the development of 
CHD. This work will guide future family-based, population-based, and functional studies of the 
genetics of congenital heart disease. As seen in other diseases such as lipid disorders, familial 
hypertension, and Lynch Syndrome, there can be functional overlap between family-based and 
population-based cases with respect to genes and pathways contributing to their etiology. Studies 
of one-of- a-kind families, like the one in this dissertation chapter, have the potential to highlight 
new genes or pathways that warrant study on an epidemiologic scale in conjunction with other 
genetic and environmental risk factors. Further, we have the opportunity to study the potentially 
diverse manifestations of the same genetic defect, which has implications for general gene 









Chapter 5. Summary and Conclusions 
 
 This dissertation applied three different quantitative approaches to identify novel genetic 
risk factors contributing to the etiology of colorectal cancer (CRC) and complex congenital heart 
disease (CHD). It showed by example how extensions of traditional epidemiological and human 
genetic study designs can be implemented to characterize unique genetic risk factors for CRC 
and CHD. Also, this dissertation demonstrated the value of both population-based and family-
based studies over the full range of  genetic variant frequencies to advance our understanding of 
germline susceptibility for these complex diseases. While the first two chapters focused on CRC 
and the latter chapter addressed complex CHD, the quantitative approaches used in this 
dissertation are applicable across a wide spectrum of complex phenotypes.  
 Chapter 2 explored risk loci for CRC through a genome-wide association study (GWAS) 
meta-analysis. This project combined germline DNA samples from two case-control studies of 
high CRC incidence populations, Ashkenazi Jews from the Molecular Epidemiology of 
Colorectal Cancer (MECC) study and non-Hispanic whites from the Colon Cancer Family 
Registry (CFR). The discovery-replication design leveraged directly measured and 1000 
Genomes Project imputed genotypes from 485 cases and 498 controls from MECC (discovery), 
1977 cases and 999 controls from CFR (discovery), and 1131 cases and 831 controls from 
MECC (replication). In the discovery stage, an inverse-variance-weighted, fixed-effects meta-
analysis was conducted on study-specific results from adjusted logistic regression models run to 




risk loci at a minimum statistical significance level of 0.05. Further, the discovery meta-analysis 
identified a novel, genome-wide significant risk locus upstream of FSTL5 at 4q32.2, which was 
sustained upon replication in an independent set of MECC samples from the CORECT 
consortium. The most statistically significant SNP from the joint discovery plus replication meta-
analysis was rs35509282 (effect allele = A; OR=1.54; p=8.2x10
-9
; MAF~9%). This chapter also 
fine-mapped the genome-wide significant signal from the combined discovery plus replication 
meta-analysis. Future studies will include further replication in other populations, deeper fine 
mapping with the GAME-ON consortium’s OncoChip, bioinformatic analysis of potentially 
overlapping biofeatures indicative of regulatory activity, and functional studies to better 
characterize this new risk locus. 
 In Chapter 3, the search for CRC susceptibility loci continued with a targeted GWAS 
approach in Ashkenazi Jews from northern Israel. MicroRNAs (miRNAs) act as key post-
transcriptional regulators of gene expression via binding to the 3’ untranslated regions (UTRs) of 
mRNAs. Single nucleotide polymorphisms (SNPs) found in the miRNA sequence and/or 
corresponding binding sites can affect the fidelity of this interaction, and evidence from 
candidate miRNA studies suggests that such SNPs may increase or decrease risk of tumor 
development. This study was designed to expand the search for miRNA-related polymorphisms 
important in the etiology of CRC across the genome and to investigate the association between 
genetic variants in miRNA target sites and colorectal cancer (CRC) risk using a novel 
genotyping platform, the Axiom
®
 miRNA Target Site Genotyping Array (237,858 markers). The 
final study sample after quality control filtering included 596 cases and 429 controls from 
MECC. The marginal association between each marker with minor allele frequency >=1% and 




for sex, age, and the first two principal components (PC) to capture fine-scale population 
structure. There were 23 markers with p-values less than 5x10
-4
, and the most statistically 
significant association involved rs2985 (chr6: 34845648; intron of UHRF1BP1) with an OR of 
0.66 and p-value of 3.7x10
-5
. Further, this study provided evidence for replication of a previously 
published locus, rs1051690 in the 3’UTR region of the insulin receptor gene INSR (OR: 1.38; p 
= 0.03), and demonstrated variability in INSR gene expression by genotype at this locus. To our 
knowledge, this was the first study to examine the association between genetic variation in 
miRNA target sites and cancer risk using a genome-wide approach. Future directions include 
expansion of the genotyped dataset, replication and fine-mapping in the GAME-ON and 
CORECT consortia, and functional studies to identify the allele-specific effects on miRNA 
binding and to find the best in vitro model.  
 Finally, Chapter 4 explored genetic risk factors contributing to the etiology of complex 
CHD. The goal of this study was to identify rare genetic variation underlying the development of 
complex CHD through whole-genome sequencing (WGS) of a family affected by hypoplastic 
left heart syndrome (HLHS) and conotruncal defects. We hypothesized that the clustering of 
these anatomically distinct lesions was attributable to a more proximal defect in cardiogenesis. 
Paired-end, WGS data was generated on the Illumina Genome Analyzer II and HiSeq platforms 
for germline DNA from a proband with HLHS (~36X average depth of genome coverage); her 
affected half-sisters with tetralogy of Fallot (~39X) and truncus arteriosus (~10X), respectively; 
her unaffected full brother (~30X); and their shared unaffected father (~33X). Sequencing reads 
were aligned to the human genome reference sequence, followed by realignment and 
recalibration. Single nucleotide variant and short indel calls were made using the Genome 




located in previously-published CHD-associated gene regions were identified. These variants 
were analyzed for co-segregation according to one of three genetic models that were consistent 
with the pedigree: 1) autosomal dominant (AD) with incomplete penetrance, 2) AD with gonadal 
mosaicism, and 3) autosomal recessive. Thirty-two variants in 29 genes co-segregating according 
to one of these models and defined as high impact and/or potentially damaging by SIFT, 
PROVEAN, and/or Polyphen-2 were highlighted as causal candidates for future validation and 
follow-up epidemiologic studies.  
 The combination of epidemiologic study design, state of the art human genetic 
techniques, advanced bioinformatics tools, and quantitative methods enabled these applied 
studies at the frontier of genetic/genomic epidemiology. In this era of genomics research, there 
exists a wide range of genotyping and sequencing technologies to measure genetic variation. 
Also, we have a multitude of techniques at our disposal to evaluate the functional consequences 
of genetic variation prior to undertaking in vitro studies. As in this dissertation, decisions 
regarding which tools and methodologies to use must be incorporated as a critical aspect of study 
design.  
 Together, these three studies advance our understanding of genetic contributions to 
complex phenotypes through detailed investigation of highly informative individual patients, 
families, and large populations. This dissertation demonstrates the value of both population-
based studies of common complex diseases and family-based studies of rare abnormalities, 
genetic studies in subgroups of the population, a focus on the full range of variant frequencies, 
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